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ABSTRACT 
This thesis applies systems approaches in order better to understand 
host-pathogen interactions in infectious diseases; it focuses on the intracellular 
bacterium Burkholderia pseudomallei, the causative agent of the human 
disease melioidosis. Little is known about the epigenetic changes in host cells 
during infection. This study assesses genome-wide patterns of the epigenetic 
marker DNA methylation in host cells following infection with B. pseudomallei. 
The studies of this thesis concern the infection of human macrophage-like U937 
cells with B. pseudomallei and the DNA methylation levels were measured 
during the early stages of infection. Analyses reveal significant changes in 
infected cells (compared to uninfected controls) at multiple locations in the host 
DNA. Most of the methylation changes in infected cells are losses rather than 
gains in methylation. Five different differential methylation patterns (constant, 
early, late, transient, and oscillatory) are identified. Differentially methylated 
sites mapped to genes that may affect virulence, e.g. genes involved in actin 
regulation, immune response, inflammatory response, and nitric oxide 
generation. The thesis also measures whole blood DNA methylation profiles of 
patients diagnosed with melioidosis in order to test the potential role of host 
DNA methylation in melioidosis. The results demonstrate that patients with 
melioidosis are separated from healthy subjects by their distinct methylation 
profiles. The differentially methylated regions reported here can potentially be 
used as biomarkers for classification and prognostication of infectious diseases.  
In addition to exploring the changes to the host, a comprehensive 
understanding of the pathogen interference and the search for 
countermeasures requires a framework that assesses how the host changes 
 3 
the pathogen metabolically. In this thesis, to understand the role of trehalose 
pathway in virulence, computational models were constructed by integrating 
kinetic information, genomics data and literature surveys. Existing kinetic 
models of the trehalose pathway were implemented and extended allowing for 
the in silico investigation of the trehalose mutant. Further, metabolic networks of 
B. pseudomallei were analysed at the genome scale to identify molecular links 
between trehalose and metabolic pathways such as glycolysis. The genome-
scale reconstruction of the B. pseudomallei metabolic network was used to 
simulate growth under different conditions and predict the effects of gene 
knockouts.  
This thesis not only expands the existing knowledge about B. 
pseudomallei infection, the novel approaches employed here will stimulate a 
wider understanding of the applications of systems biology to host-pathogen 
research and defence needs. 
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CHAPTER 1. INTRODUCTION 
 
1.1 Infectious diseases and host-pathogen interactions 
Infectious diseases are a major problem worldwide. Diverse groups of 
pathogens—bacteria, viruses, fungi, protozoa—are able to produce infections 
ranging from mild to severe conditions. Human diseases such as tuberculosis, 
malaria, HIV and neglected tropical diseases kill more than 4 million people 
every year [1]. The emergence of drug resistance [2] and the lack of effective 
vaccines [3] have intensified the need for novel approaches to understanding 
the biology driving infection and to accelerate the development of therapies.  
A major current focus in infectious disease research is host-pathogen 
interactions. Pathogens adopt various strategies to survive and replicate within 
their hosts, often subverting host cellular pathways, while the hosts initiate 
responses to control pathogen activity [4]. Bacterial pathogens usually inject 
specialized proteins—pathogenic factors—directly into host cells. These factors 
can target crucial intracellular pathways at multiple points. Hence, a more 
comprehensive picture of the functional consequences can be achieved when 
pathogen interference is evaluated in the context of the host networks it 
operates on. 
 
1.2 Systems analysis of host pathogen interactions 
Traditional approaches focus on single genes or gene-for-gene 
interactions, which are likely to play a role in the infection process. However, 
cellular functions are hardly ever dictated by single genes acting alone. Instead, 
the concerted action of multiple components comprises cellular processes that 
can give rise to biological behaviour [4]. Thus, gene-for-gene interaction models 
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are insufficient in capturing the whole picture of the function and evolution of 
pathogen interference. Systems approaches, by which genome-wide 
information is screened and integrated, is vital for understanding the complex 
mechanisms of disease. Systems biology data at the organism or cellular scale 
is often produced through system-wide (referred to as “–omic”) technologies 
and analysed by mathematical modelling. Sections 1.2.1 and Section 1.2.2 
review high-throughput screening technologies and the perspectives these offer 
in terms of host-pathogen interactions. Section 1.2.3 gives an overview of 
mathematical modelling methods and their application to host-pathogen 
research.  
 
1.2.1 -Omic Technologies 
The postgenomic era has provided a huge amount of knowledge on the 
genetic makeup of organisms. Systematic large-scale analyses allow faster and 
high-throughput screening to test hypotheses at various stages of biological 
processes [5]. Omic technologies—from whole-genome sequencing, to 
transcriptomics, proteomics and metabolomics—have been invaluable in 
deciphering the genetic underpinnings of complex biological traits [6–8].  
Next-generation sequencing (NGS) technologies have allowed the rapid 
and cheap sequencing of DNA and RNA to study the genomics of infectious 
diseases. The availability of whole genome sequences for thousands of 
pathogens has advanced the understanding of pathogenesis. For example, 
researchers identified genomic signatures pointing to the emergence of drug 
resistance [9] or have located the outbreak of a particular disease [10,11].  
Gene expression is central to biological function, meaning that 
transcriptomics has been instrumental in infectious disease research [12]. 
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Transcriptomics measures the expression levels of mRNAs, which can vary with 
external conditions. Such changes occur when the host and the pathogen meet 
[13,14]. The transcriptional response of the host or the pathogen during 
infection has been evaluated to assess the dynamics of infection, to 
characterise virulence factors, to identify biomarkers, and to study host 
immunity [12-14]. More sophisticated approaches profiled expression levels of 
the host and pathogen simultaneously [15,16]. Microarray and sequencing 
technologies are used for transcriptome-wide gene expression profiling. 
Microarrays determine the abundance of nucleic acids by hybridization to 
probes on microchips. Microarray chips have been mostly developed for large 
transcriptomes (i.e. humans, mice). While microarrays can efficiently analyse 
large numbers of genes, these genes are targets of predetermined probes. In 
contrast, sequencing techniques for transciptomics (RNA-seq) offer the 
identification of novel transcripts and are preferred for discovery analyses in 
non-model organisms such as pathogenic microorganisms [15]. In addition to 
transcriptomics, other system-level approaches, which inspect gene-protein 
interactions and metabolic pathways, have been employed to decipher the 
virulence of various pathogens [16–19].  
The precise temporal and spatial control of gene expression requires the 
concerted action of transcription factors as well as epigenetic modulators. 
Epigenetic modulators affect how genes are read without changes in the DNA 
sequence [20]. There are many types of epigenetic processes including DNA 
methylation, histone modifications, and non-coding RNA. These processes can 
alter chromatin structure and control gene expression [21]. In the drive towards 
a complete understanding of infectious diseases, it is crucial to consider the role 
of epigenetics. Despite the significant advances in epigenetic technologies and 
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evidence supporting epigenetic modulation of host-pathogen interactions, little 
is known about the epigenetic changes in host cells during infectious diseases. 
Chapters 2 and 3 of this thesis present evidence for the contribution of 
epigenetic changes to host response during infection by focusing on DNA 
methylation. As background for these chapters, Section 1.4 provides an 
overview of epigenetic mechanisms and how DNA methylation may contribute 
to host-initiated and/or pathogen-induced responses.  
 
1.2.2 Interpreting high-throughput data and network analyses 
The ample information obtained through high-throughput technologies 
brings up the next challenge: to integrate this knowledge into multi-scale models 
of host-pathogen interaction pathways and to provide a holistic understanding of 
physiological and disease states. To meet these challenges, computational 
tools have been developed. These bioinformatics methods can leverage the 
huge amounts of data for valuable analysis. In particular, statistical tests are 
being employed to determine the significance of the results (e.g. changes in 
gene expression) drawn from analyses [22]. High-throughput data are often 
high dimensional, especially in cases of complex experimental setups (e.g. 
comparisons between multiple groups of samples, time point measurements, 
etc.). Clustering analyses reduce the complexity by grouping variables based on 
their similarity in the data [23,24]. Gene ontology [25] and pathway analyses 
[26] are frequently applied to provide a biological context to the large number of 
differentially regulated genes obtained from genomics data.  
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1.2.3 In silico modelling and simulation 
While bioinformatics tools organize and aid the interpretation of these 
data, systems biology approaches adopt methods to integrate the multiple types 
of information into a mathematical format to infer properties about that system 
[27]. Thus, beyond the analysis of network organization, the available 
information can be merged into dynamic, explanatory and predictive models 
[28]. The calculation of network characteristics provides explanations for 
biological phenomena. Simulation of different scenarios enables testing of 
hypotheses, which may not be possible or feasible in laboratory experiments.  
Such mathematical models have been invaluable in studying the role of 
metabolism in host pathogen interactions [29,30]. Mathematical models of 
metabolism have been developed using two major modelling methodologies. 
Metabolic models contain either a few reactions described to a high level of 
kinetic detail (kinetic models) or a large set of reactions with little or no kinetic 
information (constraint-based models) [31].  
Kinetic models allow for dynamic simulation and control analysis. To 
build a kinetic model, rate laws need to be assigned to all reactions and the 
kinetic constants in each reaction must be determined. Extensive experimental 
data is required to characterise the mechanics of a kinetic model. For this 
reason, kinetic models are often available merely for central pathways of well-
studied model organisms, such as Escherichia coli or Saccharomyces 
cerevisiae [32,33]. Nonetheless these models offer an indispensible insight into 
the dynamic regulation of core metabolism and reveal underlying mechanisms 
of phenotypes (e.g. adaptation to carbon sources) that can be applied to a wider 
range of organisms [32,34,35].  
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On the other hand, the increasing number of fully sequenced genomes 
has allowed the construction of constraint-based models for a wide range of 
organisms [36–38]. Constraint-based models only account for the stoichiometry 
and directionality of reactions, which can be derived from genome annotations. 
These metabolic reconstructions can serve to evaluate the biosynthetic routes 
for production of toxic materials by pathogens within the host cells or to the 
survival capacities of the pathogen within the host-cell nutrient environment. 
Flux balance analysis (FBA) [39] has been the leading constraint-based tool. 
FBA calculates steady-state metabolic fluxes and can predict the growth rate of 
an organism. FBA can simulate the deletion of genes and survey the 
essentiality of reactions in various pathogens including bacterial species [40]. 
Metabolic reconstruction of pathogens such as Mycobacterium tuberculosis 
[41], Salmonella typhimurium [42], and Francisella tularensis [43] offered cost-
effective pipelines to search for potential targets for medical interventions.    
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1.3 Aims and Overview of the thesis 
This thesis applies systems approaches to enhance the understanding of 
host-pathogen interactions in infectious disease. Within the host context, 
potential host targets of either pathogen-mediated or pathogen-initiated 
epigenetic changes in the host were identified. As there were very limited 
reports in the literature on the epigenetic changes after infection, this work 
uncovers novel mechanisms of virulence of pathogens and the host response. 
In addition to exploring the changes to the host, this thesis assesses how the 
pathogen changes metabolically within the host environment. This multifaceted 
view on pathogen interference will stimulate new directions for research into 
novel disease interventions. The particular focus of this thesis is the intracellular 
bacterium Burkholderia pseudomallei, the causative agent of melioidosis; 
however, many of the approaches can be applied to other diseases and 
pathogens. 
The key objectives of this thesis are: (i) to identify genome-wide changes 
in host DNA post infection; (ii) to map temporal changes over the course of 
infection; (iii) to understand the functional significance of the interference with 
the host; and (iv) to understand the role of bacterial metabolism in virulence. 
The organisation of the thesis is as follows:  
Chapter 1 provides a literature review on host parasite interactions in 
infectious diseases and the system approaches used. Section 1.4 provides a 
background on epigenetics and DNA methylation, Section 1.5 gives motivation 
for interest in trehalose metabolism and Section 1.6 introduces B. pseudomallei.  
Chapter 2 reports a genome wide analysis of changes in the DNA 
methylation state of host cell genes following infection with the intracellular 
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pathogen B. pseudomallei in an in vitro infection model. A human macrophage 
cell line was used. 
Chapter 3 identifies DNA methylation differences associated with 
melioidosis, an infectious disease caused by B. pseudomallei. To this end, 
whole blood DNA methylation levels of patients diagnosed with septicemic 
melioidosis and healthy subjects were measured. 
Chapter 4 focuses on the metabolic network of B. pseudomallei and 
mathematical modelling approaches to understanding the role of metabolism in 
virulence. Particular emphasis is given to the trehalose pathway. The 
importance of the trehalose pathway in bacterial virulence is reviewed in 
Section 4.1.  
Chapter 5 draws the conclusions of this study and provides suggestions 
for further work. 
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1.4. Epigenetics in host-pathogen interactions 
1.4.1 Epigenetics 
Epigenetics is defined as the study of heritable phenotypes that are 
associated with changes in gene expression without changes in the DNA 
sequence [20,44]. Epigenetics refers to the extra layer of information, on top of 
the genetic code, that allows development and differentiation of diverse 
functions from the same set of instructions [45]. Epigenetic processes can alter 
DNA accessibility and chromatin structure, thereby regulating gene expression 
and activity [46]. These processes are highly dynamic and exhibit tissue-specific 
patterns [47,48]. Epigenetic information can be retained and passed on to 
offspring [49,50]. Modifications occurring through these epigenetic processes 
can dictate differentiation of different cell types from identical DNA [51]. 
Epigenetic modifications also modulate patterns of gene expression in response 
to environmental stimuli [52,53]. Such modifications are therefore vital in 
interpreting the genome under physiological and pathological conditions [54]. 
Profiling epigenetic modifications of the entire genome—the epigenome in a 
given cell—may serve as biomarkers for diagnosis and therapeutic tools [55–
57].  
Epigenetic mechanisms include DNA methylation, histone modifications 
and non-coding RNA. Histones are special proteins, which wrap eukaryotic 
DNA into chromatin structure [58]. Modifications of histones (e.g acetylation, 
methylation, phosphorylation, etc.) can result in alterations in the chromatin 
architecture inhibiting the access of the transcriptional machinery to DNA and 
ultimately affecting gene expression [21]. Furthermore, non-coding RNA—RNA 
that does not encode a protein—can be involved in controlling chromatin 
structure and gene expression [59]. This thesis focuses on DNA methylation, 
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which is described in the next section.  
 
1.4.2 DNA methylation 
In eukaryotes, DNA methylation involves the transfer of a methyl group to 
the C-5 position of the cytosine ring by DNA methyltransferases (DNMTs) and 
usually occurs at CpG sites (Figure 1.1) [60]. CpG sites are regions of DNA 
where a cytosine nucleotide occurs next to a guanine nucleotide in the DNA 
sequence. CpG islands, regions where high frequencies of CpG sites are 
clustered, are often found close to the promoters of genes, where the 
transcription machinery binds [61] and are typically unmethylated [45]. 
 
Figure 1.1. DNA methylation process. DNA methylation often occurs at 
cytosine nucleotides that are followed by a guanine nucleotide (CpG site) and 
involves the conversion of cytosine to 5’methyl-cytosine by DNA 
methyltransferase (DNMT). S-adenosylmethionine (SAM) is used as a methyl 
donor and converted to S-adenosylhomocysteine (SAH). Figure and legend 
adapted from [62].  
 
DNA demethylation can occur passively or actively: passive DNA 
demethylation can occur as a consequence of cell growth and DNA replication 
in the absence of DNA methyltransferases [63]; active DNA demethylation 
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involves enzymatic removal of methylation (oxidation mediated by TET proteins 
[64]) via intermediates [65–67] as shown in Figure 1.2.  
 
 
 
Figure 1.2. Dynamic modifications of cytosine. a. Cytosine (C) converted to 
5’methyl-cytosine (5mC) by DNA methyltransferase (DNMT), 5mC oxidized 
iteratively to 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and to 5-
carboxylcytosine (5caC); Active modification (AM) – passive dilution (PD): 
5hmC is diluted to generate unmodified C; AM – active restoration (AR): 5fC or 
5caC is excised by TDG generating an abasic site as part of the base excision 
repair (BER) process that regenerates unmodified C. b. The reactions are 
shown individually. Figure and legend adapted from [66]. 
 
DNA methylation can lead to gene silencing though several mechanisms: 
methylated CpG sites can directly prohibit transcription factor binding by 
blocking the DNA binding sites [68] (Figure 1.3a); Methyl-CpG-binding proteins 
(MBPs) can use co-repressor molecules to repress transcription [69] (Figure 
1.3b), or inhibit elongation [70] (Figure 1.3d); interactions between DNMT and 
histone modification can condense the chromatin and lead to transcriptional 
repression (Figure 1.3c) [60].  
 24 
 
 
Figure 1.3. Mechanisms of DNA methylation mediated repression. (a) DNA 
methylation inhibits transcriptional activation by directly blocking the DNA 
binding sites for transcription factors (TF). (b) Methyl-CpG-binding proteins 
(MBPs) recognize methylated DNA and recruit co-repressor molecules to 
silence transcription and to modify surrounding chromatin. (c) DNMT are linked 
to histone deacetylase (HDAC) and histone methyltransferase (HMT) and this 
can lead to chromatin modification and transcriptional repression. (d) DNA 
methylation within the body of genes can effect transcriptional elongation. MBPs 
might be involved in inhibiting elongation, either directly or by their effects on 
the surrounding chromatin structure. Figure and legend adapted from [60]. 
 
DNA methylation changes are involved in human disease as well as 
during normal development. Widely studied examples of processes controlled 
by DNA methylation are X chromosome inactivation [71], genomic imprinting 
[72], and genome integrity [73].   
 
1.4.3 DNA methylation and disease 
Cancer is among the well-known DNA methylation-associated diseases 
where CpG islands are found to be hypermethylated and general genomic 
regions are hypomethylated [74,75]. The tumor-suppressor genes are 
inactivated through methylation of their promoter regions [76]. Hypermethylation 
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and silencing of genes involved in cell-cycle regulation, chromatin remodelling, 
cell signalling, transcription and apoptosis favours tumour cells by increasing 
their genetic instability. Other pathological consequences of deregulation of 
DNA methylation are characterised in genomic imprinting disorders and repeat-
instability diseases [77].  
Recently, the role of epigenetics in host-pathogen interactions received 
attention because of its potentially profound effects on gene expression and its 
heritable nature [78,79]. Pathogens hijack host cells and control intracellular 
processes to promote their own survival and evolve phenotypic traits to adapt to 
the host environment. Conversely host cells induce signals activating the 
immune response [4]. An effective strategy used by bacteria to alter the host 
cell is to interfere with the key cellular processes at an early stage. The 
information flow that gives rise to these processes start in DNA. Hence DNA is 
an obvious target to reprogram the host cell beneficial for infection. Thus 
bacteria can affect host cell functions by directly influencing epigenetic factors 
acting on DNA such as DNA methylation. 
In the past three years, there have been a few reported studies of 
genome-wide changes in the methylation state of host cells. One study 
examined DNA methylation changes in human dendritic cells infected with a live 
virulent strain of Mycobacterium tuberculosis, the causative agent of 
tuberculosis in humans [80]. This study showed that host methylation changes 
were associated with activation of key immune factors. A similar observation 
was made by Marr et al. [81], where the methylation changes in host 
macrophages infected with the intracellular protozoan Leishmania lead to down-
regulation of innate immunity, favouring pathogen survival.  
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There are also reports of H. pylori-associated DNA hypermethylation 
[82–85]. H. pylori is a risk factor for gastric cancer [82]. H. pyroli is reported to 
mediate methylation of the E-cadherin (CDH1) tumor suppressor gene promoter 
[83]. Temporal changes in DNA methylation have been reported in key 
inflammatory response genes such as CXCL2, IL-1β, NOS2, and TNF-α. This 
evidence implies that methylation events may contribute significantly to 
establishing inflammatory responses. In another study it has been proposed 
that intestinal flow influences the methylation state of the IL-4 gene in intestinal 
epithelial cells and this results in the down regulation of TLR4 expression [86].  
Little is known about bacterial control of host cell methylation beyond 
these few studies. Yet advances in epigenetic technologies have also made 
genome-wide profiling of DNA methylation possible. Thus, it is now possible 
efficiently to identify the repertoire of genes that are differentially methylated as 
a consequence of bacterial infection. This would not only allow the identification 
of the role of epigenetic changes in regulating host cell transcription; it could 
also allow the deciphering of new mechanisms by which bacteria establish 
disease. Epigenetic changes underlying the host-pathogen relationship could be 
utilized as biomarkers for assessing the development of diseases. Within the 
heritable characteristics of these markers, it could also help our understanding 
of microbial persistence and the evolution of host immunity. By providing new 
insights into host-pathogen interactions, epigenetic studies can pave the way for 
novel strategies to prevent or treat disease.   
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1.5 Trehalose metabolism and virulence  
In addition to direct damage to the host caused by virulence factors, a 
fundamental aspect of pathogenesis is the metabolic regulation as the 
pathogens adapt to changing conditions (e.g. level of free iron, pH, carbon 
source and oxygen availability, etc.) in the host [87]. The nature of this complex 
host-pathogen interaction suggests that metabolic systems are as important as 
the virulence genes that control membrane receptors and lipids [88]. Pathogenic 
bacteria can acquire additional metabolic pathways or lose non-essential 
metabolic functions while undergoing metabolic adaptation to survive within the 
host [89]. Resistance to antibiotics can also be a result of this metabolic 
reprogramming [90]. Hence, studying bacterial metabolism is essential for 
understanding host-parasite interactions and might identify novel targets for 
anti-microbial therapies.  
A relation between trehalose metabolism and virulence traits is being 
elucidated in pathogenic species [91]. The underlying mechanisms of this 
association, however, are less clear. While biological experiments often provide 
a verbal reasoning framework within which to build theories, the complex nature 
of biological interactions increasingly requires the aid of computational models 
to comprehensively explain the biological phenomena. To this aim, Chapter 4 
first reviews the current knowledge of trehalose metabolism, which then is 
formalized into computational models and subsequently utilized to make 
predictions on the physiological behaviour 
Trehalose is a sugar present in many organisms such as bacteria, yeast, 
fungi, plants and invertebrates. Long-established functions of trehalose are 
energy storage and protection against a variety of stress conditions such as 
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heat, cold, dehydration and oxidation [92]. Moreover, in mycobacteria and 
corynebacteria, trehalose is a structural component of cell wall glycolipids. In 
recent decades, a remarkable variety of functions of trehalose have been 
shown, including the control of metabolic pathways and growth [93,94].  
More recently, the role of trehalose in pathogenic host interactions and 
virulence has begun attracting widespread interest [91,95–98]. Trehalose 
accumulation has been found to protect cells against reactive oxygen species 
[99], which are often used by host cells to kill pathogens. The abolishment of 
trehalose production results in reduced in vivo survival in pathogenic fungi 
[100–104] and plant pathogens [105]. Most of the studies relating trehalose 
metabolism and bacterial virulence focus on the Mycobacterium tuberculosis, 
where mutants in trehalose biosynthesis pathways exhibited growth defects and 
reduced ability to develop chronic infections [95,97].  
A number of metabolic pathways are present for biosynthesis and 
degradation of trehalose in different organisms [106]. Bacteria can synthesise 
trehalose via five distinct pathways (Figure 1.5.1), two of which are present in 
eukaryotic organisms [106]. Humans cannot synthesize trehalose; however, 
humans have the enzyme trehalase required for degradation of trehalose into 
glucose [107]. Because the trehalose biosynthesis pathways are absent in 
mammalian cells [108], trehalose related targets have been proposed for novel 
drug discovery [109]. 
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Figure 1.5.1. Metabolic pathways of trehalose synthesis and degradation 
(highlighted in black and in grey respectively). Ac, Archea; B, Bacteria; F, Fungi; 
P, Plants; Ap, Arthropods; Pr, Protists. * Trehalase is present in all kingdoms, 
including mammals. Figure and legend adapted from [91]. 
 
 
 
1.6 Melioidosis and Burkholderia pseduomallei 
Burkholderia pseudomallei, a member of the Burkholderia genus, is an 
aerobic, Gram-negative bacterium and the causative agent of the severe 
disease, melioidosis [110]. Melioidosis occurs after skin inoculation or inhalation 
of B. pseudomallei, which resides in soil, stagnant water, and rice paddies in 
endemic areas, mainly in Southeast Asia and Northern Australia [111]. Recent 
reports document that the prevalence of melioidosis is substantially 
underestimated, with significant implications for public health in many tropical 
developing countries as well as developed countries [112]. Furthermore, 
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Centers for Disease Control and Prevention classified B. pseudomallei as a 
category B biothreat agent [113].  
B. pseudomallei can infect the skin, spleen, liver, lungs, or can enter the 
bloodstream spreading throughout the body [111]. Signs and symptoms of 
melioidosis include cough, chest pain, high fever, headache, and skin 
abscesses [113]. The inflammatory condition in the lungs, pneumonia, is the 
common clinical manifestation of melioidosis [114]. As other infections such as 
tuberculosis commonly affect the lungs, melioidosis is often difficult to 
distinguish and has been referred to as “the great mimicker” [110]. Melioidosis 
can occur in acute and chronic forms [115]. Some infected individuals may not 
develop any symptoms; B. pseudomallei can persist in the body and reactivate 
later in life causing disease [115]. Immunocompromised individuals, e.g. 
patients with diabetes mellitus or chronic renal failure, are more susceptible 
[116]. The majority of melioidosis patients develop sepsis [117], a strong 
immune response with widespread inflammation throughout the body. A variety 
of currently available antibiotics are ineffective in treating melioidosis and 
therefore melioidosis has a high mortality rate [113]. 
B. pseudomallei is capable of surviving harsh environmental conditions 
such as prolonged nutrient deficiency [118], acidic environments [119], 
temperature extremes and dehydration [120]. The B. pseudomallei genome is 
composed of two chromosomes: a large chromosome of 4.07 megabase pairs 
is associated with core functions such as central metabolism and growth and a 
small chromosome of 3.17 megabase pairs encodes for accessory functions, 
which may provide the bacterium with the ability to adapt and survive within the 
host [121].   
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It has previously been shown that host genes involved in immune 
response, stress response and cell cycle regulation are differentially regulated 
upon B. pseudomallei infection [122]. Upon infection with B. pseudomallei, 
increased expression of cell surface molecules are observed in human 
macrophages [123]. Whole-genome transcriptional profiles showing the 
differentially expressed genes on B. pseudomallei infection, including genes 
related to inflammation, are present in the literature [124].  
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CHAPTER 2. HOST DNA METHYLATION CHANGES DURING INFECTION 
WITH BURKHOLDERIA PSEUDOMALLEI: IN VITRO INFECTION MODEL 
 
Chapter 2.1 Introduction 
At present, very little attention has been given to host DNA methylation 
changes following bacterial infection. In particular, the time course of such 
methylation changes during infection has not been addressed.  
The research work described in this thesis constitutes the first 
investigation of the role of host DNA methylation during B. pseudomallei 
infection. In particular, the following research questions represent the main 
objectives of this work: 
(1) To explore whether there are any changes in the host methylome 
following infection with B. pseudomallei.  
(2) In cases of proven DNA methylation changes during B. 
pseudomallei infection, to measure the dynamics of methylation changes. 
(3) To understand the functional significance of the methylation 
changes. 
(4) To relate methylation changes to gene expression. 
An appropriate infection model was essential in capturing the potential 
role of DNA methylation. In the current research environment, the use of human 
cells for infection assays with B. pseudomallei represents a valid approach 
[125–129]. The human macrophage cell line U937 was therefore chosen for this 
work. U937 cells are well established and documented in the literature to study 
B. pseudomallei infection [123,126]. The protocol reported by Lehmann et al. 
[130] was adopted for the setup of the infection model. U937 cells differentiate 
into macrophages; macrophages provide a good model as they are usually 
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recruited during infection in response to pathogens to initiate defence 
mechanisms. Working with a human cell line also enabled the use of 
microarrays for downstream DNA methylation analysis. 
This study was set out as follows:  
- B. pseudomallei colonies recovered from the differentiated U937 
cell monolayers were examined in order to understand the dynamics of B. 
pseudomallei infection in U937 cells. This guided the time points used for the 
discovery experiment. 
- The discovery experiment (referred to as experiment 1) aimed to 
detect changes in the methylation state of the infected cells compared to the 
uninfected controls. 
- Subsequently, a replication experiment (referred to as experiment 
2) was performed. This experiment followed the same protocol of experiment 1 
with additional sampling times, allowing for investigation of the time course of 
the infection. 
 
2.2 Methods 
2.2.1 Cell line and infection model 
The human leukemic monocyte lymphoma cell line (U937, ATCC CRL-
1593.2) was maintained in RPMI 1640 supplemented with 10% foetal bovine 
serum (FBS) at 37°C. U937 cells were differentiated to macrophage-like cells 
following exposure to 20 ng/ml (final concentration) of phorbol 12-myristate 13-
acetate (PMA) for 48h at 37°C and differentiation evidenced by increased 
adherence to tissue culture flasks.  
Overnight cultures of B. pseudomallei K96243 were diluted in L-15 
medium and added to differentiated U937 cells at a multiplicity of infection 
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(MOI) of 10. The dynamics of B. pseudomallei infection were established in 
which B. pseudomallei colonies were recovered from the differentiated U937 
cell monolayers. At 1h (T1), 2h (T2), 4h (T4) and 24h (T24) post infection, the 
cells were washed 3 times in warm phosphate buffered saline (PBS) and lysed 
with 0.1% (vol/vol) triton X-100. Serial dilutions of the cell lysate were plated 
onto LB agar to determine the intracellular bacterial cell counts. Bacterial loads 
were measured as colony forming units (CFU) at 2h, 3h, 4h, 5h, 6h, and 24h 
post infection.  
Additionally at T2, the uptake of B. pseudomallei K96243 expressing red 
fluorescent protein (RFP) [131] by U937 cells was enumerated. Cells were 
washed 3 times with PBS and overlaid with 200µl paraformaldehyde (PFA) 
0.4%, ensuring any coverslips were fully immersed.  Cells were than incubated 
at room temperature for 30 minutes. PFA was removed and coverslips were 
washed twice with PBS for 1 hour for each wash. Coverslips were removed and 
stained with 4',6-diamidino-2-phenylindole (DAPI). DAPI passes through the cell 
membrane and binds to DNA. DAPI’s blue emission labelled the nuclei of the 
host cells. Cells were visualized with epifluorescence. Eight fields of view were 
visualised and the number of uninfected or infected U937 cells were counted. 
The mean number of cells infected with bacteria was calculated. 
The data from this experiment, presented in Section 2.3.1, informed the 
time points taken for the main experiment in which samples are prepared to 
measure the DNA methylation. 
A total of eight tissue culture flasks (four for infected cells and four for 
uninfected controls) were prepared for the first set of samples for the DNA 
methylation study. An overview of the experimental setup is illustrated in Figure 
2.2.1. Uninfected controls were overlaid with L15 medium only. The cells were 
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then incubated at 37°C for 2h to allow infection. The cells were washed 3 times 
with PBS and incubated with fresh L15 medium containing 1mg/ml kanamycin 
for 2h to kill extracellular bacteria. After 2h, the macrophage cells were held in 
fresh media containing 250µg/ml kanamycin to supress the growth of 
extracellular bacteria. At T2 and T4, the cells were washed 3 times in warm 
PBS and lysed with 0.1% (vol/vol) Triton X-100. DNA was isolated using an 
AllPrep kit (Qiagen) and stored at -80ºC until required. DNA yield was 
measured using a Nanodrop instrument with measurements between 22.8–50.6 
ng/ul. This experiment was repeated, ultimately resulting in two technical 
replicate and two experimental replicate DNA samples for each time point, T2 
and T4 (a total of 16 samples). Although the Qiagen AllPrep method allows 
simultaneous isolation of DNA and RNA, RNA was not collected in this 
experiment. This was due to difficulties in handling high number of flasks in 
Biosafety Level 3 Laboratory. The challenges that emerged from this 
experiment were taken into consideration in designing the second experiment.  
 
Figure 2.2.1. Experimental setup for macrophage infection. 
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A second experiment was designed to enable verification of the results of 
the first experiment and to allow additional sampling times and collection of 
RNA. Similar procedures were followed as described above and DNA and RNA 
was collected from uninfected and infected cells at 1h (T1), 2h (T2), 3h (T3) and 
4h (T4) post infection. At T3 and T4 two types of controls were collected; 
uninfected cells administered with kanamycin and uninfected cells without 
kanamycin. For every group, 1 sample was obtained (a total of 10 DNA samples 
and a total of 10 RNA samples).  
 
2.2.2 DNA methylation profiling 
The DNA methylation profile of the host macrophage DNA was 
determined using the Infinium HumanMethylation450 BeadChip (450K) (Illumina 
Inc.). The 450K BeadChip interrogates DNA methylation at >480,000 individual 
CpG sites (loci) on the human genome.  
The first step is bisulfite treatment. Bisulfite treatment converts 
unmethylated cytosines to uracil, which is then amplified as thymine during 
whole genome amplification [132]. Methylated cytosine residues are left 
unaffected. This allows the sequencing technologies to distinguish between 
methylated and unmethylated cytosine residues [133].  
The bisulfite-converted-amplified DNA products are then applied to the 
chip and hybridised either to the methylation specific probe or to the 
unmethylation probe. Single-base extension of the probe incorporates a 
fluorescently labelled dideoxynucleotide (ddNTP). The chip is then scanned and 
the fluorescent signal is measured.  
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HumanMethylation450 BeadChip technology uses two different types of 
probes (Infinium Type I and II probe designs are illustrated in Figure 2.2.2). The 
Infinium Type I Probes have two separate probe sequence per CpG site - one 
for methylated CpG and one for unmethylated CpG. Thus, unmethylated and 
methylated DNA fragments hybridise to two different beads and produce a red 
signal. Infinium Type II Probe measures unmethylated and methylated DNA 
fragments by the same bead but produce a green signal for the methylated 
fragment and a red signal for the unmethylated fragment. Type II probes are 
more efficient as they use one probe sequence per CpG site: however Type I 
probes perform better in measuring CpG dense regions [134].  
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Figure 2.2.2. The design of Infinium methylation assays (See legend on 
next page) 
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(See figure on previous page) (a) The genomic location of the gene, BRCA1. 
CpG sites (CpG Loci) are marked in green. The probes present in 
HumanMethylation450 (HM450) and MethylationEPIC (EPIC) platforms are 
marked in red and blue, respectively. Two probes targeting adjacent CpG sites 
in the BRCA1 promoter were circled in pink dotted line. These are two different 
types of probes (Infinium Type I and II probes). (b) Infinium I (cg21253966) and 
Infinium II (cg04110421) probes; the targeted CpG sites are highlighted in 
green. Each probe is designed to hybridise a 50 bp DNA sequence, underlined 
in blue, downstream of the targeted CpG site. (c) In bisulfite conversion the 
unmethylated cytosine (C) is converted into uracil and later amplified as thymine 
(T). The unmethylated signal detection for the cg21253966 probe is 
schematically represented on the left panel. The unmethylated bead probe (U) 
sequence is designed to match bisulfite converted DNA sequence of the 
unmethylated locus. The hybridisation of a bisulphite converted unmethylated 
DNA fragment to the bead enables single base extension and incorporation of a 
ddNTP labelled nucleotide matching the nucleotide immediately upstream of the 
target CpG site; in this case incorporation of an A nucleotide and signal 
detection in the RED channel. Hybridisation of the methylated bead probe (M), 
on the other hand, results in mismatch at the 3′ end of the probe and inhibition 
of single base extension. Detection of the methylated signal, shown on the right 
panel, follows similar steps. (d) For Infinium II probes, the unmethylated and 
methylated signals are measured by the same bead (U/M). The bead probe 
sequence is designed to match bisulphite converted DNA of both the 
methylated and unmethylated locus. This is achieved by making the cytosine of 
the target CpG site the single base extension locus and replacing cytosines of 
all other CpG sites within the probe sequence with degenerate R bases that 
hybridise to both T (representing unmethylated and converted cytosine) and C 
(representing methylated and protected cytosine) bases. Single base extension 
and incorporation of ddNTP labelled A nucleotide matching the unmethylated 
and converted cytosine at the target CpG site results in signal detection on the 
RED channel. The detection of the methylation signal, shown on the right panel, 
is the same except that in this case single base extension results in 
incorporation of ddNTP labelled G nucleotide matching the methylated and 
protected cytosine at the target CpG site and signal detection on the GREEN 
channel. Figure and legend adapted from Pidsley et al. [134].  
 
To profile the samples on the array, 500ng of genomic DNA was sodium 
bisulfite converted using the EZ-96 DNA Methylation kit (Zymo research, CA, 
USA). Replicates were processed together on the same array to reduce batch 
effects. The data were extracted using the GenomeStudio (2010.3) methylation 
module (1.8.5).  
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2.2.3 Data acquisition and normalisation 
All quality control checks were performed using R (version 3.2.3). Signal 
intensities were imported into R using the methylumi package. For each 
sample, the distribution of the methylated and unmethylated signals were 
plotted to check whether there were any extreme outliers.  
For each CpG site a β-value was calculated, which is the ratio of the methylated 
probe intensity (M) to the overall intensity (sum of methylated (M) and 
unmethylated (U) probe intensities) [135]. For an ith interrogated CpG site: 
!! = max (!! , 0)max (!! , 0)+max (!! , 0)+ ! 
where Mi and Ui are the intensities measured for the ith methylated and 
unmethylated probes, respectively. For Infinium Type I Probe, the M and U 
intensities are signals produced by two different bead types and are reported in 
the same colour (red). For Infinium Type II Probes, M and U are the intensities 
of the green and red fluorescent signals, respectively. Any negative values that 
might arise from global background intensity subtraction are reset to 0. When 
both methylated and unmethylated probe intensities are low, a constant offset α 
(α = 100 as recommended by Illumina [135]) was added to the denominator to 
regularise the β-value. Ultimately, the β-value between 0 and 1 reflects the 
methylation level of each CpG site: a value of zero represents that all measured 
loci in the sample are unmethylated and a value of one represents that all 
measured loci in the sample are methylated.  
Quality control checks and quantile normalisation were implemented 
using R WateRmelon package [136]. Samples with more than 1% of sites with a 
detection p-value greater than 0.05 were removed, as were probes with 1% of 
samples with a detection p-value greater than 0.05 (following guidelines 
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established by Bibikova et al. [137]). Probes were removed if they had a bead 
count less than 3 in 1% of samples. Cross-hybridizing probes were removed 
[138], leaving 425496 probes for analysis.  
2.2.4 Data analysis 
Reasoning that larger differences are potentially more biologically 
meaningful [139], differentially methylated positions (DMPs) between infected 
and control cells were identified using a Δβ cut-off of 0.1. The analysis pipeline 
is summarised in Figure 2.2.3.  
Figure 2.2.3. Schematic of the data analysis pipeline.  
 42 
DMPs identified at T2 and T4 in the first experiment, were compared to 
the corresponding probes at the same time point in the second experiment.  
Probes exhibiting a Δβ change in the same direction with |Δβ|>0.1 were taken 
for further analysis. Correlations of Δβ values between the two experiments 
were measured using Pearson’s correlation coefficient. This set of replicated 
DMPs was tested for enrichment of genomic regions using a two-tailed Fisher’s 
exact test, comparing DMPs to the frequency of all probes on the Illumina 450K 
array.  
DMPs with consistent up or down-methylation at all time points T1, T2, 
T3 and T4 were identified. The temporal methylation patterns were assigned to 
categories based on the change in score at successive time points. As many of 
the differential methylation patterns found in disease or environmental factors 
are characterized by smaller changes, in the range of 5% [81], this criterion was 
selected to identify temporal patterns of differential methylation. Signatures with 
more than 5% differential methylation at all time points were classified as, 
constant hyper- (+5%) or constant hypo-methylated (-5%) probes. Signatures 
with more than 5% differential methylation at early time points (T1, T2, T3) and 
no change at the T4 time point were classified as early response probes. 
Signatures with no response at the T1 time point and with more than 5% 
differential methylation at later time points were classified as late response 
probes. Signatures with no response at T1 and T4 and more than 5% 
differential methylation at T2 or T3 were classified as transient responses. The 
remainder of the patterns were classified as oscillatory probes.  
Candidate genes were assigned to the probes using the GREAT 
software [140], which allots genes to genomic regions taking into account the 
functional significance of cis-regulatory regions. A probe level analysis was 
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employed using a custom script to determine the functional significance of the 
differentially methylated positions in experiment 1. Genes were assigned to 
functions using the Gene Ontology. Gene ontology annotations were 
downloaded from the Gene Ontology Consortium database [25]. Probes were 
matched with Gene Ontology terms.  
To measure the association between the top differentially methylated 
probes and a given biological function, the right-tailed Fisher Exact Test [141] 
was used where the analysis is applied to focus probes against all probes, as 
outlined in the contingency table (Table 3.2.1). For each function (gene ontology 
term), a p-value is calculated, which is a measure of the likelihood that the 
association between the set of focus probes (here, the set of differentially 
methylated probes) and the given function is due to random chance. p-values 
less than 0.05 are considered to be statistically significant, non-random 
associations. The odds ratio (OR) is another measure of association and can be 
calculated from Table 3.2.1 as, 
!" =  !!! !!"!!" !!! 
n11 is the number of probes that are associated with the given function in the set 
of focus probes, 
n21 is the number of probes that are not associated with the given function in the 
set of focus probes, 
n12 is the number of all probes on the array that are associated with the given 
function, 
n22 is the number of all probes on the array that are not associated with the 
given function. 
The greater the odds ratio is, the more significant is the association.  
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Table 3.2.1. Contingency table. For each functional term a contingency table 
is constructed, where the number of probes (n) that are associated and not 
associated with the function are enumerated for the focus set and the set of all 
probes.  
 Focus probes All probes Row totals 
Probes associated 
with a function n11 n12 row1 
Probes not 
associated with 
that function 
n21 n22 row2 
 
Column totals col1 col2 N 
 
 
An alternative method for gene ontology term enrichment analysis was 
performed using the Bioconductor package GOseq [142]. GOseq employs a 
similar method to probe level analysis explained previously. Both methods 
measure gene ontology enrichment by Fisher’s exact test, while the probe level 
analysis counts the number of probes for a given ontology term, GOseq counts 
the number of genes. GOseq method is adapted to determine the functional 
significance of the conserved iDMPs. Enriched gene ontology terms are 
selected based on the criteria of having a p-value<0.05.  
Redundant gene ontology terms were removed and the non-redundant 
gene ontology terms were clustered using semantic similarity measures (the 
simRel score) with the REVIGO software tool [143]. 
 
2.2.5 Measuring gene expression using Real-time PCR 
100ng total RNA was reverse transcribed from each sample using the 
Superscript VILO cDNA synthesis kit (Invitrogen, Paisley, UK). Quantitative 
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real-time PCR assays specific to the DDHA2 and TOLLIP transcripts (Assay 
identifiers Hs00203889_m1 and Hs01553188_m1 respectively) were purchased 
from Life Technologies (Paisley, UK). PCR reactions contained 2.5ml TaqMan 
Universal Mastermix (no AMPerase) (Applied Biosystems, Foster City, USA), 
0.9mM each primer, 0.25mM probe and 1ml cDNA in a total volume of 5ml. 
Samples were tested in three technical replicates. PCR conditions were a single 
cycle of 95°C for 10 minutes followed by 50 cycles of 95°C for 15 seconds and 
60°C for 1 minute. The amount of each transcript was then quantified in RNA 
samples relative to the endogenous control genes beta microbglobulin (GUSB; 
assay identifier Hs00984230_m1) and beta glucuronidase (GUSB; Assay 
identifier Hs00939627_m1). These control genes were chosen on the basis of 
their stability under test conditions, which was determined empirically. 
Quantifications were carried out by the Comparative Ct approach and data were 
normalised to the median value for samples unexposed to bacteria. 
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2.3 Results 
2.3.1 Infection Model 
To understand the dynamics of B. pseudomallei infection, U937 cells 
were infected with B. pseudomallei K96243 expressing red fluorescent protein 
(RFP). U937 cells were matured and differentiated to adopt the characteristics 
of mature human macrophages [123]. The cells were activated with interferon 
gamma (IFN-γ). The activation of macrophages with IFN-γ dramatically 
enhances the ability of the cells to control infection with B. pseudomallei [144]. 
At 2 hours (T2) post infection, 74% of the human cells were infected; most 
infected cells were infected with multiple bacteria (Fig. 2.3.1 - the blue stain 
shows the nuclei of the host cells and the red stain shows the bacteria). The 
number of intracellular bacteria was 106 CFU/ml at T2 (Fig. 2.3.2). After 4 (T4) 
or 6 hours (T6) post infection, the number of intracellular bacteria had declined 
to 103 CFU/ml. No intracellular bacteria were recovered at 24 hours post 
infection (T24). This experiment guided the design of the first experiment to 
measure DNA methylation. As there were no previous reports on when the DNA 
methylation changes might be occurring, for our discovery experiment 
(Experiment 1) two time points were chosen - a first time point when the 
infection is established (T2) and a later time point when there is reduction in the 
number of intracellular bacteria (T4). As the number of viable bacteria level off 
after 4 hours post infection (T4), a similar response would be expected at T4 
and after T4. 
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Figure 2.3.1. Infected cells at T2. The proportion (74%) of cells infected at T2 
determined by microscopy. Blue stain represents the nuclei of the host cells and 
the red stain represents the bacteria.  
 
 
Figure 2.3.2. Bacterial loads at different time points in U937 cells infected 
with B. pseudomallei (MOI = 10). Bacterial load was measured as colony 
forming units (CFU).  
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2.3.2 DNA extraction 
Simultaneous isolation of DNA and RNA was practiced on test samples 
using Trizol. The test samples were B. pseudomallei infected mouse 
macrophages (2h post infection) from another study conducted by Olivia 
Champion. Signs of degradation of the DNA samples and contamination were 
observed (DNA quantified using Nanodrop, Fig. 2.3.3). The project collaborators 
found similar problems when using DNA samples that had been stored in Trizol 
solutions. According to current status of the art, the Qiagen AllPrep method is 
established as an improved method for preparing genomic DNA for methylation 
studies compared to Trizol extraction [145]. The use of Qiagen AllPrep 
overcame the DNA degradation and contamination issues. 
 
Figure 2.3.3. Quantification of DNA concentration and quality control. DNA 
isolated using the Trizol extraction method. DNA peak measured by the 
Nanodrop instrument. 
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2.3.3 DNA methylation discovery experiment (Experiment 1) 
DNA from the infected or uninfected (controls) U937 cells was collected 
from two technical replicates and two experimental replicates at the selected 
time points T2 and T4 as explained in Section 2.3.1. Although initially, the study 
was planned to simultaneously measure DNA methylation and gene expression 
levels, RNA was not collected in Experiment 1. This was due to experimental 
difficulties arising from organizing a line of set-ups to simultaneously collect high 
number of samples in Biosafety Level 3 laboratory. The challenges faced in this 
experiment were taken into consideration for the design of the follow-up 
experiment in which RNA samples were collected. 
DNA methylation was quantified using an Illumina 450K 
HumanMethylation array, with pre-processing, normalisation and stringent 
quality control undertaken as explained in Section 3.2.3. Differentially-
methylated positions (DMPs) between infected and uninfected cells at T2 or T4 
were identified. For each position (CpG sites), the significance of differential 
methylation was measured using Student’s t-test. The positions were ranked by 
mean methylation difference and p-value. Widespread large changes were 
identified in host cell DNA methylation following infection, top 25 positions were 
reported in Fig. 2.3.4. 
 
 
 
 
 
 
 50 
 
(a) 
 
(b) 
 
Figure 2.3.4. Top 25 genes at T0 and T2. a) Top 25 genes ranked by mean 
methylation difference and p-value at T2. b) Top 25 genes ranked by mean 
methylation difference and p-value at T4. The x-axis is labelled with the gene 
name and the CpG cite ID. The left y-axis corresponds to the difference in mean 
methylation levels between infected and uninfected cells (Δβ = mean βinfected - 
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mean βuninfected). The right y-axis reports the p-values measured using Student’s 
t-test. 
 
Next, the uninfected samples at T2 were compared to uninfected 
samples at T4. Ideally one would expect that for control samples, the 
methylation levels do not change in time, so that the only factor affecting the 
methylation state is infection. However, there were a few CpG sites with 
methylation changes in uninfected cells from T2 to T4. These changes could be 
due to the antibiotic being introduced after the T2 samples had been taken. This 
would not pose an issue as our main focus is the comparison between infected 
and uninfected cells. Thus, when the infected and uninfected cells at T4 were 
compared, both groups contain antibiotic and its effect is cancelled.  
Nonetheless, uninfected controls with and without kanamycin were included for 
the replication experiment to explore any effects the antibiotic stress can have 
on the host DNA.   
Different p-value cut-offs were applied to enumerate the DMPs in Table 
2.3.1. A high number of t-tests being performed simultaneously can result in a 
large number of observations, which will have low p-values due to chance. To 
correct for these random events that falsely appear significant (false positives), 
multiple testing correction methods are frequently applied [146]. A statistical 
confidence measure is reported using false discovery rate (FDR) estimation 
[147], summarized in a q-value. The q-values were calculated using the qvalue 
package in R [148]. None of the CpG sites had a significant q-value (q-value < 
0.05 considered significant as it is a widely accepted threshold for genomewide 
studies [149]). However this is not surprising, as CpG sites are not independent; 
many of the multiple testing algorithms are too stringent, especially considering 
our small sample size [150]. Based on the statistical or effect size cut-offs 
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applied, a different interpretation can be given to the data [151]. Within the 
limitations of this study (i.e small sample size), in this chapter DMPs were 
identified on the basis of reproducible large methylation differences to maximize 
the chances of obtaining biologically meaningful results. In Chapter 3, 
alternative approaches are employed such as regional analysis, in which 
differential methylation is considered significant when identified on large 
genomic regions rather than on single CpGs.  
 
Table 2.3.1. Number of DMPs identified for different p-value cut-offs. p-
values were calculated using Student’s t-test. 
p-value <0.0001 <0.001 <0.01 <0.025 <0.05 <0.1 <1 
Number 
of 
probes 
at T2 
27 274 2853 7649 15989 34713 456107 
Number 
of 
probes 
at T4 
18 133 1635 4694 10670 25139 456107 
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Mean methylation differences at T4 were plotted against the differences 
at T2 in Figure 2.3.5. Probes with conserved mean methylation differences 
greater than 0.1 in the same direction at both time points T2 and T4 (coloured in 
red in Figure 2.3.5) were selected as the focus probes. GREAT gene annotation 
was used to annotate all probes with ontology terms downloaded from Gene 
Ontology. To measure the association between the differentially methylated 
probes and a given biological function, the right-tailed Fisher’s Exact Test was 
used. p-values less than 0.05 were considered statistically significant. Top 25 
enriched functions were listed in Table 2.3.2. 
 
 
Figure 2.3.5. Scatter plot of the mean methylation (beta) difference (Δβ T2 
vs Δβ T4). |Δβ| values greater than 0.1 are highlighted. Red - positive 
correlation (|Δβ|>0.1 at both time points in the same direction); green - negative 
correlation (|Δβ|>0.1 at both time points in the opposite direction); blue – 
|Δβ|>0.1 at one time point but not the other.  
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Table 2.3.2. Functional annotation of the top probes conserved in the cells 
colture experiment at time points T2 and T4. 
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2.3.4 Validation with pyrosequencing 
A technical verification for the 450K Human Methylation Array was 
designed to target the two top methylated probes detected in Experiment 1. The 
top methylated probes for time point T2 and T4 were annotated with genes 
FASTKD3 and FAM110B respectively. Pyrosequencing assays were designed 
using the PyroMark Assay design software (Qiagen). The initial steps of DNA 
methylation analysis by pyrosequencing are bisulfite conversion and PCR. To 
optimize the PCR, bisulfite conversion and PCR were performed on test 
samples. Figure 2.3.6 shows the PCR products amplified using the two primers 
(FASTKD3 and FAM110B). Using the optimised PCR conditions, PCR 
amplification was performed successfully on bisulfite treated DNA samples 
prepared in Experiment 1 as shown in Figure 2.3.7. Pyrosequencer monitors 
the real-time incorporation of nucleotides and signals release of pyrophosphate 
molecules during DNA elongation, visualises peaks corresponding to the 
nucleotide sequence. Pyrosequencing analyses for these samples were not 
successful as peak detection failed when the PCR products were run on the 
pyrosequencer.  
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Figure 2.3.6. Test samples - PCR products amplified using the primers 
indicated.  
 
 
 
Figure 2.3.7. U937 macrophage samples - PCR products amplified using the 
primers indicated.  
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A second line of investigation was employed for pyrosequencing 
analysis. B. pseudomallei infected and control mice lung tissue samples were 
donated by a collaborator who had already generated transcriptomic data [152]. 
These were from mice acutely infected with B. pseudomallei by the intranasal 
route day 1 and day 3 post infection. Uninfected control mice received pyrogen-
free saline (PFS). DNA was isolated from a total of 16 tissue samples using 
Trizol extraction and were quantified using Nanodrop (Table 2.3.3).  
 
Table 2.3.3. DNA from mouse lung samples.  
Experiment 
Harvest                
(day post 
infection) 
Mouse Lung 
samples DNA Conc. ng/ul 
LC1111 1 L1 PFS 47.8 
LC1111 1 L2 PFS 29.4 
LC1111 1 L3 PFS 27.5 
LC1111 1 L4 PFS 31.5 
LC1111 1 L15 Bps 53.2 
LC1111 1 L16 Bps 44.6 
LC1111 1 L17 Bps 11.4 
LC1111 1 L18 Bps 26.6 
LC1111 3 L25 PFS 73.5 
LC1111 3 L26 PFS 48.4 
LC1111 3 L27 PFS 50.7 
LC1111 3 L28 PFS 89.4 
LC1111 3 L39 Bps 87.4 
LC1111 3 L40 Bps 72.7 
LC1111 3 L41 Bps 195.4 
LC1111 3 L42 Bps 121.8 
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Two genes were selected as targets for the pyrosequencing analysis, 
C1QTNF2 and TRIM10. These genes exhibited differential methylation in 
Experiment 1 in this study (methylation measurements shown in Figure 2.3.8) 
and also were differentially expressed on the mouse transcriptomic data. The 
pyrosequencing assay for TRIM10 failed, but results were obtained for 
C1QTNF2. A few samples failed, because the DNA concentration was low. 
Using the pyrosequencing assay, the methylation levels for the infected 
(Bps) and control mouse lung samples (PFS) were measured across the six 
CpG sites targeted in the promoter region of C1QTNF2. Higher methylation 
levels were found infected samples (Figure 2.3.9). Previous data showed that 
there is a significant decrease in methylation in the body region of C1QTNF2 
(Figure 2.3.8 A) on infected human macrophages and C1QTNF2 expression 
was down-regulated in infected mice (Transcriptomics data obtained from the 
collaborators showed that C1QTNF2 had an expression fold change of -4.057 
in Day 1 Bps-infected mice and -7.145 in Day 3 Bps-infected mice). These 
results align with suggestions in the literature that increased methylation in 
promoter regions is generally associated with down-regulation of expression, 
whereas methylation in gene body regions is positively correlated with gene 
expression [153,154].  
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 (a) 
 
(b) 
 
 
Figure 2.3.8. Methylation levels of genes C1QTNF2 (a) and TRIM10 (b) 
selected as targets for pyrosequencing methylation analysis on mouse 
lung samples. The x-axis lists the methylation sites associated with the gene 
and the y-axis is the normalized methylation level measured in Experiment 1 
(U937 human macrophage).  
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Figure 2.3.9. Pyrosequencing results on mouse lung samples. Target gene: 
C1QTNF2. BPS: Burkholderia pseudomallei infected; PFS: controls. 
 
 
2.3.5 Experiment 2 - Differential methylation patterns 
Next a replication experiment (Experiment 2) was performed following 
the same protocol as Experiment 1, but with additional sampling times and 
samples enabling to control for antibiotic effects. DNA and RNA were 
simultaneously collected at 1 hour (T1), 2 hours (T2), 3 hours (T3) and 4 hours 
(T4) post infection.  
Reasoning that larger differences are potentially more biologically 
meaningful, infection-induced DMPs (iDMPs) were characterised by a greater 
than 10% DNA methylation difference between infected and uninfected cells. In 
Experiment 1, 10,279 iDMPs were identified (54% hypo-methylated; 46% 
hyper-methylated) at T2 and 4850 iDMPs (57% hypo-methylated; 43% hyper-
methylated) at T4, with 642 iDMPs at both T2 and T4 (Figure 2.3.10). Using 
data from Experiment 2 a stringently filtered dataset of 388 iDMPs was obtained 
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as conserved between the two experiments, which were used for subsequent 
analysis. These DNA methylation changes were highly correlated across both 
experiments (T2: r=0.83, p<0.0001 – see Figure 2.3.11a; T4: r=0.73, p<0.0001 
– see Figure 2.3.11b). 264 iDMPs were conserved at T2, 141 iDMPs were 
conserved at T4 and 17 iDMPs were conserved at both T2 and T4. 
 
 
Figure 2.3.10. Quantification of infection-induced DMPs (iDMPs). * iDMPs 
conserved between the two experiments.  
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Figure 2.3.11. Methylation changes in experiments 1 and 3 at replicated 
iDMPs. (a) Changes at T2. (b) Changes at T4. 
 
The methylation levels of the uninfected samples were plotted in a 
heatmap (Figure 2.3.12). This shows that differential methylation occurs in 
heavily, partially and sparsely methylated regions. When the methylation levels 
of infected samples are compared to uninfected samples (Figure 2.3.13), in 
general, there are hypo-methylated sites.  
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Figure 2.3.12. Heatmap of methylation levels of control samples at iDMPs. 
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Figure 2.3.13. Heatmap of methylation levels of infected and control 
samples at iDMPs. 
 
In addition to quantifying DNA methylation at T2 and T4 in experiment 1 
and 2, we also profiled samples collected at T1 and T3 in experiment 2. In 
experiment 2, only one sample was collected for each group. As in both 
experiments measurements have been taken at T2 and T4, DMPs identified at 
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T2 and T4 in the first experiment were compared to the corresponding 
measurements at the same time point in the second experiment. Validated 
probes were assigned to categories based on the change in score at 
successive time points.  
Several distinct patterns of DNA methylation across the four time points 
were observed at the conserved iDMPs (Table 2.3.3.). As there is more than 
one sample for each group in experiment 1, the standard deviations of the 
methylation levels were represented by error bars. Signatures with more than 
5% differential methylation at all time points were classified as, constant hyper- 
(+5%) or constant hypo-methylated (-5%) probes. Signatures with more than 
5% differential methylation at early time points (T1, T2, T3) and no change at 
the T4 time point were classified as early response probes. Signatures with no 
response at the T1 time point and with more than 5% differential methylation at 
later time points were classified as late response probes. Signatures with no 
response at T1 and T4 and more than 5% differential methylation at T2 or T3 
were classified as transient responses. The remainder of the patterns was 
classified as oscillatory probes. 
21 probes (5.41%) showed consistent changes in DNA methylation 
across all time points in both experiments (for example cg17676428 (Fig 12a) 
and cg21823425 (Figure 2.3.14. b)). 23 probes (5.93%) showed large changes 
at the early time-points that diminished at the later time-points (for example 
cg15470658 (Figure 2.3.14. c) and cg11630696 (Figure 2.3.14. d)). 55 probes 
(14.18%) displayed a lag in response, with DNA methylation changes only 
occurring at the later time points after infection (for example cg14113958 
(Figure 2.3.14. e) and cg06284169 (Figure 2.3.14. f)). 99 probes (25.52%) 
showed a transient response (for example cg14173033 (Figure 2.3.14. g) and 
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cg00782124 (Figure 2.3.14. h)). Finally, 190 probes (48.97%) had an oscillatory 
response (for example cg00400832 (Figure 2.3.14. i) and cg15392054 (Figure 
2.3.14. j)). The losses of methylation were more prominent compared to gains in 
DNA methylation patterns, especially in iDMPs exhibiting a constant response. 
Immune processes should be tightly regulated to avoid excessive damage to 
the host. Inflammatory processes, for example, are necessary to initiate a 
protective response against harmful bacteria. However, prolonged and 
excessive inflammation can damage bystander normal tissue [155].  The 
patterns demonstrated in Figure 2.3.14 allow evaluation of the role of DNA 
methylation in the kinetics of immunoregulation. Components associated with 
early DNA methylation response can play role in eradicating bacteria. Late 
responses can terminate processes such as inflammation after the bacteria 
have been cleared. Relative to the burden of infection certain responses are 
elevated or dampened at different times. Transient and oscillatory responses 
could point the time to key events during infection with B. pseudomallei. 
Polymerisation of the host actin, for instance, is a process that provide bacteria 
motility in the host cytosol after bacteria evade host innate response [156]. 
Methylation patterns mapping to the time course of host responses can 
decipher characteristic features of B. pseudomallei in their ability to infect host 
cells.  
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Figure 2.3.14. Differential methylation patterns. Each panel shows a 
representative gene, with a particular temporal methylation pattern, as 
discussed in more detail in the text. The error bars represent the standard 
deviation of the methylation levels of the first experiment samples: (A) constant 
hypo-methylation; (B) constant hyper-methylation; (C) early response hypo-
methylation; (D) early response hyper-methylation; (E) late response hypo-
methylation; (F) late response hyper-methylation; (G) transient response hypo-
methylation; (H) transient response hyper-methylation; (I) & (J) oscillatory 
response.  
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Table 2.3.3. Number of iDMPs assigned to categories based on differential 
methylation patterns. Signatures with differential methylation at all time points 
(1 hour (T1), 2 hours (T2), 3 hours (T3) and 4 hours (T4) post infection) were 
classified as constant hyper- or constant hypo-methylated probes. Signatures 
with differential methylation at early time points (T1, T2, T3) and no change at 
the T4 time point were classified as early response probes. Signatures with no 
response at the T1 time point and with differential methylation at later time 
points were classified as late response probes. Signatures with no response at 
T1 and T4 and differential methylation at T2 or T3 were classified as transient 
responses. The remainder of the patterns were classified as oscillatory probes. 
Category number of probes hyper-methylated hypo-methylated 
A: constant 
response 
21 3 18 
B: early 
response 
23  10 13 
C: late response 55 11 44 
D: transient 
response 
99 42 57 
E: oscillatory 
response 
190 NA NA 
 
 
In experiment 2, additional samples were collected. These were DNA 
from uninfected cells not treated with the antibiotic kanamycin. For the set of 
iDMPs no differences were found between the uninfected cells treated with 
kanamycin and the uninfected cells without kanamycin. 
To explore the biological significance of the genes mapping to the set of 
iDMPs, genes were annotated with gene ontology (GO) terms and searched for 
over-representation of categories using the package GOseq, which weights 
genes based on the number of probes per gene. Enriched biological functions 
were identified using semantic similarity, which provides a measure of functional 
similarity (Figure 2.3.15). Functionally similar GO terms appear closer in the 
plot. Functions related to cellular responses to stress can point to the host cell 
detecting the presence of bacteria. Interleukin related components play a role in 
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stimulating immune responses. This can show that DNA methylation processes 
can initiate or be a result of inflammation. The regulation of adhesion molecules 
can suggest that the bacteria is gaining motility in the host cell through 
manipulating the host DNA.  
 
Figure 2.3.15. Gene ontology terms enriched (p<0.05) in genes mapping to 
conserved iDMPs. The colour scale represents the p-values calculated using 
GOseq. The non-redundant gene ontology terms are clustered using REVIGO. 
 
 
2.3.6 An alternative approach for identifying differential methylation 
patterns: Multi-scale Gaussian Mixtures for identifying differentially 
methylated sites 
Given the small sample size of the study, it is crucial to develop the right 
approach to detect the differentially methylated probes. So far, the measure to 
assess methylation changes was the effect size, the magnitude of methylation 
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level differences (Δβ) between the infected and the control samples. Assessing 
the significance of these changes is also important in identifying DMPs.  In this 
section, the multi-scale Gaussian mixtures method was used to identify DMPs, 
based on statistical significance. This method was proposed by Yang et al. 
[157] to extract homogeneous and heterogeneous gene expression patterns 
across species. The sum and difference of expressions are modelled using 
multi-scale Gaussians. In this section, the multi-scale Gaussian model was 
applied to reveal the differential methylation patterns between the infected and 
control cells. 
The model is composed of two Gaussians, shown as red and blue curves 
in Figure 2.3.16, which have identical means, but different variances. The 
Gaussian with the smaller variance is referred as the null density (red) and the 
Gaussian with the larger variance (blue) as the alternative density. A Bayesian 
learning process is initiated for each difference vector and the null and 
alternative densities are estimated after convergence is achieved. For each 
methylation site, the probabilities that it belongs to the null or alternative 
distribution are calculated. In the histogram of the methylation sites in Figure 
2.3.16, sites with alternative probability greater than the null probability are 
defined as the differentially methylated sites (these correspond to the area 
outside the red curve under the blue curve).  
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Figure 2.3.16. Histogram of methylation level differences modelled with a 
Multi-scale Gaussian Mixture Model. 
 
Using the Multi-scale Gaussian Mixtures method on the methylation data 
presented in this chapter, 5269 methylation sites were obtained, which are the 
top 1% of the sites ranked by their posterior probability. Figure 2.3.18 is a 
heatmap of all the differentially methylated sites presented as a Venn diagram 
(Figure 2.3.17) when the sites are seriated by their methylation difference. This 
reveals patterns such as demethylation at T1, methylation at T2 and T3, 
demethylation at T4 etc. The results obtained with the Multi-scale Gaussian 
Mixtures method were similar to the results from previous analyses where the 
focus was on the probes that have big methylation differences. Even though 
same DMPs were identified, using the Multi-scale Gaussian Mixtures method a 
significance measure was assigned to these DMPs. This verified that the big 
differences identified previously are statistically significant.  
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Figure 2.3.17. Venn diagram showing the number of differentially 
methylated sites across the time points (top 1% ranked by posterior 
probability). 
 
 
Figure 2.3.18. Heatmap showing the Δβ values for differentially methylated 
sites across the time points.  
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2.3.7 Effect of differential methylation on gene expression  
2.3.7.1 Measuring expression levels using qPCR 
In order to establish whether the altered methylation patterns produced 
corresponding changes in expression levels, the expression levels of two genes 
(TOLLIP, DDAH2) were quantified using quantitative real time PCR. These 
genes were selected from the group of constant response iDMPs. mRNA levels 
in infected and uninfected samples. At T1 and T2, neither of the selected genes 
showed a significant change in expression levels (Fig 2.3.19). DDAH2 showed 
elevated expression levels in infected cells at T3 and T4, TOLLIP showed 
elevated expression levels in infected cells at T4. Both genes thus exhibited a 
delayed effect on gene expression following the alteration of DNA methylation. 
This effect was inversely correlated with the Δβ values at the differentially 
methylated sites.  
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Fig 2.3.19. Gene expression levels following altered methylation patterns 
for DDAH2 (A) and TOLLIP (B) in infected and uninfected cells. Red bars: 
Δβ values. Grey bars: fold expression.  
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2.3.7.2 Comparison with publically available transcription data 
The iDMPs were compared with transcriptomic data from a previous 
study of B. pseudomallei infection in humans which identified 2604 human 
genes, that were differentially expressed in patients with septicemic melioidosis 
[158]. Of these, 76 genes were annotated to the iDMPs we identified in our 
study. These included genes involved in immune system processes (BCL11B, 
CDKN1C, GLMN, HLX, IL1R2, IRF8, MAEA, MEF2C, MR1, NBEAL2, PRKCH, 
PTGDR2, STK3, TNFSF8, TRIM27), response to stress (ADRB2, APBB1IP, 
DTNBP1, FBXO31, MARCH1, MSRA, PKD2, SCARB1, ZMYND11), and 
inflammatory response (CD44, HDAC4, HIF1A, IL18RAP, TOLLIP, IER3, 
NT5E). 
 
2.3.8 Comparison with publically available DNA methylation changes 
during infection with other pathogens  
Innate immune cells, such as macrophages or dendritic cells, are 
recruited in response to pathogens to initiate defense mechanisms. While this 
chapter explored DNA methylation changes in macrophages, a recent study 
identified epigenetic regulation in human dendritic cells before and after in vitro 
infection (18 hours post infection) with Mycobacterium tuberculosis [80]. The 
proportion of iDMPs compared to the total number of sites probed was 
comparable to that in this chapter (0.000912 in this chapter; 0.000649 in the M. 
tuberculosis study). There weren’t any stringently filtered iDMPs which were 
identical in cells infected with B. pseudomallei or with M. tuberculosis. However, 
when we considered the genes to which these iDMPs mapped, we identified 
121 genes (median distance of ~95 kb from the nearest transcription start site) 
that showed differential methylation in both studies. These included genes 
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involved in T cell responses (BCL11B, FOXO1, KIF13B, PAWR, SOX4, SYK), 
actin cytoskeleton organization (ACTR3, CDC42BPA, DTNBP1, FERMT2, 
PRKCZ, RAC1), and cytokine production (FOXP1, IRF8, MR1) (Fig 2.3.20). 
 
 
Figure 2.3.20. Gene ontology terms enriched (p<0.05) in genes annotated 
to the iDMPs in B. pseudomallei and M. tuberculosis infections. The colour 
scale represents the p-values calculated using GOseq. The non-redundant 
gene ontology terms are clustered using REVIGO. 
 
Another recent study examined DNA methylation changes in human 
macrophages infected with L. donovani, an intracellular parasite capable of 
regulating the host defense (Marr et al). This study reported 733 probes with 
significant methylation changes between infected and uninfected cells [19]. Of 
these, 4 were differentially methylated in our study, at all time points (Table 
2.3.4). These probes, which were all hypo-methylated, were in the vicinity of the 
TOLLIP, DIP2C, DAGLB and SFRS16 genes. These genes play important roles 
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in regulating the innate immune response (TOLLIP and DAGLB) or transcription 
(DIP2C and SFRS16). 
 
Table 2.3.4. CpG sites with differential methylation in live infected 
versus uninfected human macrophages in L. donovani infection [19] 
and in B. pseudomallei infection (this study). 
 
  
L. donovani 
infection B. pseudomallei infection 
CpG site 
UCSC 
RefGene 
name 
Δβ Δβ at T1 Δβ at T2 Δβ at T3 Δβ at T4 
cg1767642
8 TOLLIP -0.1326 -0.0839 -0.2025 -0.1765 -0.1304 
cg2656108
2 DIP2C -0.0837 -0.0407 -0.1724 -0.2340 -0.1897 
cg2274127
2 DAGLB -0.0871 -0.0400 -0.1170 -0.1343 -0.1178 
cg2698535
4 SFRS16 -0.1000 -0.0609 -0.1734 -0.2026 -0.1717 
 
 
2.4 Discussion 
This chapter demonstrates that there are reproducible significant 
changes in host macrophage DNA methylation, at multiple CpG sites in the host 
cell genome, following infection with B. pseudomallei. The results not only 
provide support for the importance of DNA methylation in understanding 
infection, but also reveal the dynamics of these changes during the early stages 
of infection.  
Infection induced differentially methylated probes (iDMPs) occur in 
heavily, partially, and sparsely methylated regions. Most of the methylation 
changes in infected cells are losses rather than gains in methylation. This trend 
is in good agreement with previous studies on cells infected with other 
pathogens. Indeed, similar hypo-methylation motifs were seen during M. 
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tuberculosis infection [80]. Furthermore Marr et al. reported a larger proportion 
of hypo-methylated CpG sites in L. donovani infected macrophages [81]. 
Comparison of M. tuberculosis and B. pseudomallei induced changes in 
methylation patterns revealed that although a number of common genes were 
differentially methylated, there were no conserved iDMPs. However, neither 
presence nor lack of correlation can be interpreted too strongly, due to the 
different complexities associated with each dataset. These studies used 
different cell types and hence we cannot discount the possibility that there 
would be conserved iDMPs if the experimental conditions were identical.  
iDMPs showing the greatest changes in DNA methylation were found to 
be in the vicinity of genes involved in inflammatory responses, intracellular 
signalling, apoptosis and pathogen-induced signalling. Toll-interacting protein 
(TOLLIP) plays an important role in the regulation of innate immunity and 
therefore with early responses to pathogens. Increased expression of TOLLIP 
has been reported in humans infected with B. pseudomallei [5]. The precise role 
of TOLLIP in protective immunity is still being clarified. One function of the 
protein is to interact with IL1RI, TLR2 and TLR4 after lipopolysaccharide (LPS) 
activation, thereby modulating the NF-KB and JNK signaling pathways [20]. The 
role of B. pseudomallei LPS in virulence [21] and the activation of TLR2 and 
TLR4 signalling during B. pseudomallei infection is well documented [22-24]. It 
is possible that the differential methylation of TOLLIP we have seen modulates 
the early immune response to B. pseudomallei LPS.  The finding that TOLLIP 
was also differentially methylated in L. donovani infected cells may reflect the 
other roles of this protein in regulating other parts of the innate immune 
response [20]. Further work is required to investigate whether differential 
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methylation of TOLLIP occurs following infection with a broader range of 
prokaryotic and eukaryotic pathogens.  
A previous study found that the alternative pathway of macrophage 
activation is activated after infection with Leishmania, and that this is 
characterised by the induction of genes including DAGLB (encoding 
diacylglycerol lipase beta) [25]. The roles of the classical and alternative 
pathways of macrophage activation in controlling B. pseudomallei infection are 
not known. However, the pattern of growth of B. pseudomallei in cells we have 
seen is consistent with macrophage activation. The findings presented in this 
chapter lend weight to the suggestion that this protein plays a role in the 
pathogen-common pathways of macrophage activation [25].  
Two of the enriched functions identified in this chapter are cell adhesion 
and cell communication, categories that include genes involved in actin related 
functions and programmed cell death. B. pseudomallei is known to promote the 
polymerisation of host actin at one pole of the bacterium in an ARP2/3- 
dependent manner [26]. This enables motility of the bacteria and is essential for 
the uptake of bacteria into cells and the spread of bacteria within and between 
cells. Gene ontology results presented in this chapter demonstrated that the 
differential methylation of several genes are involved in actin binding or 
polymerisation. These genes included CDC42BPA a component of the BLOC-1 
complex, which can interact with WASH - a regulator of ARP2/3 [27] and 
ACTR3, a major component of the ARP2/3 complex [28]. Differential 
methylation was also found for one of the central regulators of actin 
polymerisation, the PAK1 p21-activated kinase [29].  
A range of genes associated with the immune response to infection were 
differentially methylated. These include genes encoding cytokines, chemokines 
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and their receptors (CCR4, IL1R2, IL18RAP, TNFSF15, TNFSF8, CCL28) and 
signalling pathways (CASP8AP2, TOLLIP, SYK, ZBP1, MAP4K4, MBIP). B. 
pseudomallei is an intracellular pathogen, and professional phagocytes are 
believed to be an important niche for growth and survival in the host [30,31]. 
Host interferon gamma plays a key role in the control of B. pseudomallei 
infection [32,33] and suppression of the host innate response to B. 
pseudomallei  infection has previously been attributed to downregulation of the 
type I interferon gamma signalling pathway by the bacterial effector TssM [34]. 
Previously, CD44high CD8 T-cells have been shown to be an important source of 
interferon gamma [35] and this chapter presents evidence of differential 
methylation of CD44. There were also evidence of differential methylation of a 
number of genes (IRF-8, IFNE and ZBP1), which are involved in the regulation 
of interferon gamma expression. These findings provide new insights into the 
possible molecular mechanisms underpinning this suppression.  
The DDAH2 gene encodes an enzyme in the nitric oxide generation 
pathway and it is known that nitric oxide has potent antibacterial activity against 
B. pseudomallei [36,37]. The differential methylation of the gene encoding the 
NOX4 NADPH oxidase that we have seen, might explain the activation of this 
enzyme in phagocytes infected by the bacterium [38]. 
Another important feature of disease caused by B. pseudomallei is the 
ability of the pathogen to establish chronic or persistent infections. This 
suggests that B. pseudomallei is able to subvert the host immune response to 
infection. Our results provide new insights into how the host cell functions are 
modulated. The differential methylation of genes involved in memory T-cell 
responses, such as CD44, FOXO1 and FOXC1, might contribute to the inability 
of the host to mount responses capable of clearing infection.  
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We also found differential methylation of genes associated with 
ubiquitination of proteins targeted for degradation, including the SPSB4 and 
WSB1 gene products which are associated with substrate recognition, and the 
NEDD4L and SIAH1 genes encoding ubiquitin ligases. The deamidation of the 
NEDD8L protein by a B. pseudomallei type III effector protein (CHBP) has 
previously been demonstrated, and this triggers apoptosis of host cells [39]. 
However, the modulation of host cell ubiquitination has also been associated 
with the suppression of host immunity [40], and the downregulation of the NF-
kappaB/type I IFN signalling pathways has been attributed to the ubiquitination 
of signalling molecules [34]. The findings in this chapter demonstrate that 
methylation may contribute to modulation of the ubiquitination pathway. 
In summary, this chapter provides new insight into the extent to which infection 
with a bacterial pathogen results in differential methylation of host cell DNA. The 
findings indicate that differential methylation of host DNA occurs on a much 
greater scale than previously suggested. This would certainly raise interest in 
investigating DNA methylation during infection with other pathogens. To unravel 
the most accurate signatures of infection, it is important to determine whether 
these methylation changes are a general host response to infection or 
pathogen-specific responses. Whether differential methylation is a 
consequence of the direct interaction of bacterial methyltransferases with host 
cell DNA, or the consequence of modification of host cell methyltransferase 
activity awaits investigation. The findings presented in this chapter can serve to 
develop DNA methylation based biomarkers for diagnosing melioidosis. These 
biomarkers are more specific and sensitive than commonly used protein 
biomarkers [159]. Therefore they have great potential to be used in clinical 
diagnostic tests and in the development of specialised drugs.  
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CHAPTER 3. HOST DNA METHYLATION CHANGES DURING 
MELIOIDOSIS: IN VIVO INFECTION MODEL  
  
3.1  Introduction 
Because of its nonspecific and diverse clinical presentation, melioidosis 
is often hard to diagnose. A variety of antibiotics are ineffective in treating 
melioidosis and the disease has a high mortality rate. Studies emphasise the 
importance of early diagnosis in appropriate treatment and improved disease 
outcome [160]. 
There is growing recognition for the benefits of identifying biomarkers 
specific to infection in accelerating the development of diagnostic assays and in 
obtaining faster and more accurate diagnostic tests. Several studies have 
aimed to identify blood-based biomarkers for septicaemia [161–163], which is 
the most common presentation of melioidosis. Sepsis represents a pattern of 
response by the immune system to infection. Pro- and anti-inflammatory 
cytokines and chemokines have been found to play a role in sepsis. Recent 
studies employed whole blood transcriptome profiling to unravel the regulation 
of the immune system during sepsis [161–163]. These studies revealed 
potential transcriptional responses in sepsis, including signatures distinguishing 
septicemic melioidosis from sepsis caused by other infections [124].   
Despite these efforts, the pathogenesis of sepsis is not yet fully 
understood. Recently, the investigation of the epigenomic information in blood, 
particularly DNA methylation, emerged as a means of understanding the 
molecular mechanisms underlying human health and disease. DNA methylation 
signatures in blood have been identified for a wide range of other diseases 
[164–167]. 
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The motivation behind this chapter is that identifying DNA methylation 
differences associated with complex infectious diseases will improve clinical 
diagnosis. To this end, this chapter investigated the association of whole blood 
DNA methylation with melioidosis. Analysis of DNA methylation in melioidosis 
patients can facilitate development of accurate biomarkers for detection of B. 
pseudomallei infection. These DNA methylation-based biomarkers can signal 
disease-specific sites, which cannot be detected using transcriptome profiling.   
 
3.2  Methods 
3.2.1 Samples demographic 
For this study, whole blood samples of 41 individuals, who were part of a 
larger study at Khon Kaen University, were recruited. Signed, written consent 
was obtained from all of the participants and the project was approved by the 
ethics committee. DNA samples were prepared under the supervision of Prof. 
Ganjana Lertmemongkolchai at Khon Kaen University. The samples consisted 
of 28 control subjects without a history of melioidosis and 13 patients diagnosed 
with melioidosis sepsis. Sepsis is defined using the same criteria outlined by 
Pankla et al. [168], namely presentation with two or more of the following criteria 
for the systematic inflammatory response syndrome: fever (temperature >38°C 
or <36°C), tachycardia (heart rate >90 beats/minute), leukocytosis or 
leukocytopenia (white blood cell count ≥12 x 109/l or ≤4 x 109/l). Anonymised 
DNA samples were shipped to the UK with additional patient data. This data 
included the following: age, gender, race, source of infection and underlying 
disease(s).   
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3.2.2 DNA methylation analysis  
Genome wide methylation levels of infected and uninfected samples 
were profiled using using the Infinium HumanMethylation450 BeadChip (450K) 
(Illumina Inc.) as explained in Chapter 2. Briefly, DNA was sodium bisulfite 
converted using the EZ-96 DNA Methylation kit (Zymo research, CA, USA). 
Post-hybridisation allelic-specific single-base extension of the probes 
incorporates a fluorescent label enabling detection. Red and green channel 
intensity files were obtained for each sample in the. idat file format. 
 
3.2.3 Data acquisition and normalisation 
All quality control checks were performed using R (version 3.2.3). Signal 
intensities were imported into R using the methylumi package. For each 
sample, the distribution of methylated and unmethylated signals were plotted to 
check whether there were any extreme outliers.  
For each CpG site a β-value was calculated as explained in Section 
2.2.3. Quality control checks and quantile normalisation were implemented 
using the dasen function of the wateRmelon package [136]. Samples with more 
than 1% of sites with a detection p-value greater than 0.05 were removed, as 
were probes with 1% of samples with a detection p-value greater than 0.05. 
Probes were removed if they had a bead count less than 3 in 1% of samples. 
Further problematic or uninformative probes were filtered out. These were non-
specific CG probes (those without a proper Illumina identifier, cgXXXXXXX), 
probes with common SNPs (Minor allele frequency (MAF) >0.05 in an Asian 
population) in the single (or multiple) bp extension of the CpG site (a ±10bp cut-
off was used) [169], and cross-hybridising probes [138,170]. Finally, probes on 
sex chromosomes were removed, leaving 394048 probes for further analysis.  
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3.2.4 Unsupervised analysis 
To detect patterns in methylation data, hierarchical clustering and 
principal component analyses were used. The β-values were used to calculate 
the Euclidean distance between different samples. This distance is used to 
group samples in hierarchical clustering and specifies dissimilarity between 
samples. Principle component analysis (PCA) is an algorithm that enable simple 
exploration of the data by reducing the dimensionality but retaining most of the 
variation [171]. Principal components represent directions along which variation 
in the data is observed and they are widely used in genome-wide studies to 
visualise similarities and differences between samples [24]. PCA was performed 
using prcomp function in R. The first two principal components—PC1 and 
PC2—, where the variation is the data is maximal, were plotted against each 
other.  
 
3.2.5. Cell composition estimates and linear model 
Differentially methylated positions (DMPs) were identified by comparing 
uninfected and infected samples. A linear regression model was fit to the data 
controlling for the effects of age, sex, type 2 diabetes status, cell counts, and 
batch effect using the R limma package. The DNA methylation age of the 
samples were measured using Horvath’s DNA methylation age calculator with 
the advanced analysis in blood [172]. Raw β-values (all probes on the 450K 
array) and a sample annotation file were uploaded to Online Age Calculator 
[172]. The cell counts (CD8.naive, CD8pCD28nCD45Ran, PlasmaBlast, CD4T, 
NK, Mono, Gran) were calculated using the methods of Houseman et al. [173]. 
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3.2.6 Enrichment analyses in genomic regions 
Probes annotated to regions (Illumina annotations were used) were 
tested for enrichment of DMPs using a two-tailed Fisher’s exact test, compared 
to the frequency of probes in all annotated probes on the Illumina 450K array.  
3.2.7 Gene Ontology analysis 
Gene ontology and pathway enrichment analysis were performed using 
the Bioconductor package missMethyl [174]. The package missMethyl was 
recently published and it adopts the goseq method to HumanMethylation450 
array. The goseq method was discussed in Section 2.2.4. For the enrichment 
analysis performed in Chapter 2, goseq was adopted using a custom script. In 
this chapter, missMethyl was used which employs the same methodology as 
the script employed in Chapter 2. The results from missMethyl and goseq 
analyses were in good agreement. Enriched gene ontology terms were selected 
based on the criteria of having a p-value <0.01. Redundant gene ontology terms 
were removed and the non-redundant terms were clustered using semantic 
similarity measures (the simRel score) using REVIGO [143]. 
 
3.2.8 Regional analysis 
Enrichment analyses are more effective in identifying significant 
associations between DNA methylation and gene expression when applied on 
genomic regions rather than single positions [175]. The risk of spurious 
associations can be reduced when genes are identified as differentially 
methylated when they map to multiple DMPs located closely. A sliding window 
approach was employed to determine differentially methylated regions. This 
approach combines p-values of neighbouring CpG sites using Brown’s method 
[176] and provides significance for the given genomic region (window) [175]. 
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Each window is centred around the target CpG extending upstream and 
downstream by 200 bp. Brown’s method [176] is an extension of Fisher’s 
combined probability test (FCPT) [177]. FCPT combined p-values from a group 
of independent statistical tests into one test statistic. This method is 
successfully used for identifying differentially expressed genes [178]. In 
contrast, this method can be unreliable to combine differentially methylated 
positions, as these may be dependent. Brown’s method [176] is an 
approximation FCPT for combining p-values that are not independent.  
  
3.3  Results 
3.3.1 Subject characteristics 
A total of 41 subjects consisting of 28 uninfected controls and 13 patients 
diagnosed with septicemic melioidosis (BP) were selected for the methylation 
assay. The 28 uninfected controls were 13 healthy donors (H), 15 patients with 
type 2 diabetes (T2D), a well-documented risk factor for melioidosis. Subject 
characteristics are summarised in Table 3.3.1. The analyses in this chapter 
focused on identifying differentially methylated positions (DMPs) associated 
with infection. 
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Table 3.3.1. Characteristics of individuals included in the study. 
 
 
3.3.2 Unsupervised analysis 
To determine whether DNAm profiles of septicemic melioidosis patients 
were distinct from those of healthy individuals and individuals with T2D, we 
carried out hierarchical clustering and principal components analyses.  
The set of 394048 CpG sites that passed the quality checks was used to 
cluster the samples according to the similarities in DNAm profiles (Figure 
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3.3.1a). This molecular classification was compared with the phenotype of the 
samples: out of the thirteen infected samples, eleven samples were clustered 
together. Two outlying T2D samples (DM08_0004 and DM08_003) were 
excluded from subsequent analyses as these samples had lower beta density 
compared to the other samples (Figure 3.3.1b).  
 
 
Figure 3.3.1. Clustering of the samples. (a) Hierarchical clustering. (b) 
Density of methylation levels. (c) Principal component analysis of DNA 
methylation profiles.  
 
Furthermore, PCA was performed on methylomes on the set of 394048 
CpG sites. The first two principal components explained 19.4% (PC1) and 
11.1% (PC2) of the variability, and a distinct response to infected samples 
compared with uninfected samples was observed (Figure 3.3.1c). The 
molecular classification obtained through hierarchical clustering (Figure 3.3.1a) 
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confirmed that patients with septicemic melioidosis were separated from 
uninfected controls. There was no separation of healthy controls compared to 
T2D.  
3.3.3. Identifying differentially methylated positions (DMPs) 
The association of whole blood DNAm with melioidosis was examined 
locus-by-locus at 394048 individual CpG sites. For this, linear regression 
models were used, in which the dependent variable was β-value and the 
independent variable was melioidosis status, adjusted for age, sex, type 2 
diabetes status, batch effect and cell counts. Age and cell counts were 
calculated using the method proposed by Horvath [172] (correlates with the 
chronological age, Figure 3.3.2) and Houseman [173], respectively. The 
distribution of p-values calculated using regression models for each site is 
shown in Figure 3.3.3.  
 
 
Figure 3.3.2. Chronological age versus age calculated using the method 
proposed by Horvath [172] . 
 91 
 
 
 
Figure 3.3.3. Manhattan plot. The distribution of p-values calculated using 
linear regression models.  
 
Similarly, to investigate whether T2D caused DNAm changes in the host 
epigenome, T2D samples were compared to healthy controls using linear 
regression where the methylation levels were adjusted for age, sex, batch effect 
and cell counts. 
As evidenced by the Volcano plots (Figure 3.3.4) that display –log10 p-
values versus coefficient estimates, there were larger effect sizes when 
comparing melioidosis samples and controls. In contrast, no significant different 
methylated CpG sites were identified when comparing T2D versus healthy 
subjects. 
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Figure 3.3.4. Volcano plots. (a) –log10 p-values versus coefficient estimates in 
melioidosis subjects. (b) –log10 p-values versus coefficient estimates in T2D 
subjects. 
 
Next, the number of differentially methylated CpGs between melioidosis 
samples and controls was quantified. As an optimum level of significance for 
epigenome-wide association studies has yet to be established, we explored 
different thresholds for mean methylation level difference (Δβ) and p-value. As 
demonstrated in Figure 3.3.5, larger and more statistically significant differences 
are mainly losses in methylation (hypomethylation) rather than gains 
(hypermethylation). In fact, out of the top 100 differentially methylated positions 
ranked by p-value and absolute Δβ (Table 3.3.2), only two show 
hypermethylation. Mean methylation levels, Δβ, and p-values were uploaded to 
the Integrative Genomics Viewer (IGV). The MAD1L1 gene appears to have 
multiple DMPs within the top 100 positions (Figure 3.3.6).   
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Figure 3.3.5. Number of differentially methylated positions obtained using 
different thresholds for mean methylation level difference (Δβ) and p-
value. 
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Table 3.3.2. Top 100 ranked DMPs. 
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Figure 3.3.6. The MAD1L1 gene visualised using the Integrative Genomics 
Viewer (IGV). For each position, the mean methylation difference Δβ and 
corresponding p-value are plotted. Positions with >10% DNA methylation 
difference between groups with p<0.05 are marked in the DMP track. 
 
Reasoning that larger differences are potentially more biologically 
meaningful, infection-induced DMPs (iDMPs) in melioidosis were defined as 
DMPs characterized by >10% DNA methylation difference between groups with 
p<0.05. We identified 801 such DMPs (78% hypomethylated, 22% 
hypermethylated). To better understand the observed methylomic patterns, a 
heatmap was generated for the DMPs (Figure 3.3.7). Differential methylation 
occurs at heavily, partially and sparsely methylated regions. Note that the 
majority of differentially methylated sites are hypomethylated.  
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Figure 3.3.7. Heatmap of DMPs in melioidosis with >10% DNA methylation 
difference between groups with p< 0.05.  
 
The DMPs were not uniformly distributed across the genome (Table 
3.3.3). Significant over-representation of infection-induced DNA methylation 
was at probes located in the gene body of genes (compared to the frequency of 
positions in all probes on the Illumina 450K array analysed, relative enrichment 
(95% CI) = 1.33, p=5.11 x 10-6).  
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Table 3.3.3. DMPs in melioidosis by genomic feature. 
 
 
To explore the biological significance of the genes mapping to the set of 
iDMPs, iDMPs were annotated with their corresponding gene ontology (GO) 
and pathway term, and searched for over-representation of categories using the 
package GOseq, which weights genes based on the number of probes per 
gene. Enriched biological functions are summarised and visualised in Figure 
3.3.8 using semantic similarity, which provides a measure of functional 
similarity: functionally similar GO terms appear closer in the plot. Most of the 
enriched functional networks are relevant to immune processes. Functions such 
as response to stimulus and defense response shows that the host cell is 
reacting to bacteria. These processes instruct responses that would initiate 
programmes of cell death. Pyroptosis is an inflammatory response initiated in 
the presence of intracellular pathogens. Thus, there is a clear antimicrobial 
response in the host cell. Pathogens can inhibit pyroptosis to improve their own 
survival. Host and the pathogen compete to regulate pyroptosis [179]. DNA 
methylation can be the underlying mechanism for the tight control of processes 
such as pyroptosis, which determines important physiological outcomes such as 
life or death of the host. Another way of interpreting the functional significance 
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of iDMPs is mapping them to pathways. Pathways are more specific compared 
to gene ontology terms. KEGG pathways enriched in iDMPs are listed in Table 
3.3.4. Toll-like receptor signalling is part of the immune system process. 
Pathogen invasion is sensed by Toll-like receptors  [180]. Pathways such as T-
cell receptor signalling, TNF signalling regulate cytokine production and 
ultimately determine cell survival [181]. As there are iDMPs mapping to these 
pathways (Table 3.3.4) , this provides evidence for the role of DNA methylation 
in regulating key events during infection. 
 
Figure 3.3.8 Gene ontology terms enriched in genes mapping to DMPs 
(p<0.01). The colour scale represents the p-values calculated using 
missMethyl. The non-redundant gene ontology terms are clustered using 
REVIGO. 
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Table 3.3.4. KEGG Pathways enriched (FDR<0.01) in DMPs (p<0.05 and Δβ 
> 0.1). 
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3.3.4 Regional analysis 
After an initial analysis of global trends and identification of DMPs, 
differentially methylated regions (DMRs) were identified. DMRs exhibit 
differences in DNA methylation on larger genomic regions rather than on single 
CpGs. For this, the p-values were combined for each of the CpGs within size 
ranges of few hundred bases using Brown’s Method, such that neighbouring 
CpGs with similar differences give rise to more significant results as explained 
in Section 3.2.8.  
 
 
3.3.5 Comparison with transcription data 
To assess whether methylation expression levels change in response to 
infection, the transcriptome data from the same cohort were analysed (out of 
the 41 subjects, 28 transcriptional profiles were available (9 melioidosis, 9 
healthy, 10 T2D)).  
PCA analysis was performed on 7252 transcripts to explore whether 
transcriptional profiles exhibit a distinct response in melioidosis patients in 
comparison to controls. There was no separation of melioidosis samples 
compared to controls (Figure 3.3.9). While the transcriptomic profiles were not 
distinct between the groups, the methylomic profiles were distinct in melioidosis 
patients compared to healthy controls, as shown in Section 3.3.2. This attests to 
the benefits of measuring DNA methylation for detection of biomarkers for 
melioidosis.    
To test for differential expression, melioidosis and controls were 
compared using the Mann-Whitney U-test. We did not find any statistically 
significant differentially expressed genes between the groups.  
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Figure 3.3.9. Principal component analysis of transcriptional profiles. 
 
3.3.6 Comparison with other pathogens 
A recent study identified epigenetic regulation in human dendritic cells 
before and after in vitro infection (at 18 hours after infection) with 
Mycobacterium tuberculosis. There were not any DMPs, which were identical in 
whole blood of melioidosis patients and in dendritic cells infected with 
Mycobacterium tuberculosis (Figure 3.3.10). However, when the genes to which 
these DMPs mapped were considered, 122 genes showed differential 
methylation in both studies but at different sites. These genes are likely to play 
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roles in pathogen-generic responses. Similar responses are expected, as 
melioidosis is known to mimic tuberculosis [182]. However, as the differential 
methylation occur in different sites, these markers can be utilised to differentiate 
B. pseudomallei infection from M. tuberculosis.  
 
Figure 3.3.10. Comparison with publicly available DNA methylation 
changes during infection with M. tuberculosis. 
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3.3.7 Weighted Gene Correlation Network Analysis  
Candidate biomarkers are usually identified by measuring differential 
regulation in disease cases compared to controls. The analyses presented in 
this chapter, so far, adopted this methodology and measured differential 
methylation. An alternative approach to identify biomarkers is to find clusters 
(modules) of highly correlated genes and relating these modules to external 
traits (i.e. disease status). Weighted Gene Correlation Network Analysis 
(WGCNA) is a method designed to analyse complex large gene expression 
data sets [183]. WGCNA identifies interacting genes by computing their 
correlation patterns (Pearson Correlation Coefficient). It has been successfully 
applied to methylomic data to identify age-related co-methylation modules 
[172]. In this section WGCNA analysis was applied to find co-methylated probes 
in melioidosis.  
 WGCNA R package was used to create modules of co-methylated 
probes; 42 modules were identified. These modules are labelled in colours. 
Table 3.3.6 lists the number of probes in each module. The grey module 
includes 130470 probes, which were not assigned to any module. Figure 3.3.11 
shows the association of module eigengenes—the first principal component 
calculated from the DNA methylation values of all samples of that module—to 
the disease status. Each row corresponds to a module. Numbers in Figure 
3.3.11 report the correlations of the module eigengene and traits with p-values 
in parentheses. The most significant negative correlation for melioidosis status 
(bp) was observed for the turquoise module and the most significant positive 
correlation was observed for the midnight blue module. No significant 
correlation was observed for diabetes status (dm) and underlying disease (dm). 
This shows that there are clusters of co-methylated probes that are associated 
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with the melioidosis status. As there are no significant associations with other 
diseases, modules highly correlated with melioidosis status can be utilised to 
find biomarkers specific to melioidosis.  
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Figure 3.3.11. Module-trait relationship. bp: melioidosis; dm: diabetes 
T2D; ud: underlying disease. Color coded by correlation of the module 
eigengene (rows) and traits (columns). 
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In Figure 3.3.12, each point represents a probe in the given module 
(Figure 3.3.12a: turquoise; (b) midnightblue). For each probe the module 
membership is defined as the correlation between its DNA methylation value 
and module eigengene of the given module.   
 
  
 107 
(a) 
 
(b) 
 
Figure 3.3.12. Each point represents a probe in the given module (Figure 
3.3.12a: turquoise; (b) midnightblue). For each probe the module membership 
is defined as the correlation between its DNA methylation value and module 
eigengene of the given module.    
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3.4 Discussion 
This chapter reports DNA methylation profiling as a promising approach 
to understand the pathogenesis of infection. Epigenetic signatures have been 
shown to remain stable long after they have been established [184,185]. In this 
study, molecular classification analysis showed non-separation of healthy 
control methylomes compared to T2D methylomes and separation of healthy 
controls and T2D methylomes compared to septicemic melioidosis methylomes, 
attesting to the existence of distinct signatures of infection. On the cohort 
analysed, no distinct transcriptional patterns in melioidosis patients were found. 
These results suggest DNAm changes related to infection can be more stably 
propagated through, compared to gene expression changes; thus DNAm 
profiles can provide reliable robust markers for classification and 
prognostication of infectious diseases.  
The findings reported here also suggest that most of the DNAm 
differences in melioidosis patients are losses rather than gains in methylation. 
This is consistent with earlier reports of in vitro infection of macrophages with B. 
pseudomallei. Similar trends have been documented during infection with other 
pathogens [80,81]. The comparison of DMPs identified in this study with iDMPs 
identified in in vitro infection of macrophages with B. pseudomallei revealed no 
conserved DMPs. This may be due to the tissue-specific nature of epigenetic 
markers.  
It was also found that DMPs were significantly enriched in the gene body 
regions. DNA methylation and gene expression are often found to be positively 
correlated [186].  
A consensus has yet to be reached regarding optimal strategies for 
identifying differential methylation in disease association studies. Here, both 
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position and region-based approaches were adopted. Although focusing on 
DMRs reduces the risk of false positives, and changes across a region are 
more likely to control chromatin conformation and gene expression, the 
changes occurring at single CpG positions have not been discounted. Such 
changes at individual CpGs can be critical for functional variation. Moreover, 
although Illumina 450K covers 99% of RefSeq genes, it targets <2% of the CpG 
sites present in the human genome. Such technologies with sparse coverage of 
many genomic regions can be more suitable for interrogating single sites rather 
than regions. Although the p-values reported here do not reach the genome-
wide significance estimated in many genome wide association studies, this is 
not surprising given the moderately small number of samples. Nonetheless, few 
genes were found with multiple, large consistent differences between 
melioidosis patients and controls.  
Position and region-based approaches combined highlighted genes that 
are markedly differentially methylated. As listed in Table 3.3.2, Mitotic Arrest 
Deficient Like 1 Gene (MAD1L1) was hypomethylated at multiple positions in 
gene body region. Regional analysis also showed that there are multiple 
differentially methylated regions in the vicinity of MAD1L1 (Appendix A). 
MAD1L1 plays a role in cell cycle control. Deregulation of MAD1L1 can result in 
mitotic checkpoint failure. Hypo-methylation of MAD1L1 has been demonstrated 
in M. tuberculosis infected dendritic cells [187]. Downregulation of MAD1L1, 
thereby disrupting proliferation and cell cycle progression in host cells, has 
been suggested as an immunoevasive strategy employed by H. pylori [188]. B. 
pseudomallei can induce host cell cycle arrest via T3SS effector CHBP, a cell-
cycle inhibitor [189]. It is possible that differential methylation of host MAD1L1 
can play a role in B. pseudomallei-mediated cell cycle inhibition.  
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It was found that a range of genes associated with the immune response 
is differentially methylated in melioidosis patients. These genes were involved in 
hyper-inflammatory and immunosuppressive responses, which are associated 
with sepsis. Epigenetic processes are hypothesized to play a role in the fine-
tuning of key biological processes. Such tight control is required for 
inflammatory responses, where the activation of inflammasome is crucial for 
pathogen recognition, while excessive inflammation can cause tissue damage. 
Upon infection of the host, the innate immune system engages with receptors 
such as Toll-like receptors (TLRs), NOD-like receptors (NLRs) and AIM2-lie 
receptors (ALRs) [190]. The role of NLR4 in the pathogenesis of B. 
pseudomallei is well documented [191–193]. NLR4 regulates a pro-
inflammatory form of cell death called pyroptosis via the activation of caspase-1 
in the early phase of B. pseudomallei infection [191]. Furthermore, activation of 
AIM2 has been demonstrated to control pyroptosis in Francisella tularensis 
[194]. This work suggests that differential methylation of NLR4, AIM2 and 
proinflammatory cytokine TNF can contribute to the fine control of host defense 
during infection. 
Neutrophils are an essential part of the innate immune defense against 
many bacteria. Upon activation, neutrophils release neutrophil extracellular 
traps (NETs), which can entrap and damage bacteria [195]. It has been 
previously reported that B. pseudomallei induces formation of NETs [196] and 
there are abundant levels of NET-related markers in plasma from melioidosis 
patients [197]. Evidence was found for the differential methylation of such 
components, Elastase (ELANE), Myeloperoxidase (MPO) and Azurocidin 1 
(AZU1). AZU1 encodes proteins with antibacterial activity contained in Azurophil 
granules. Azurophil granules are specialized lysosomes of the neutrophil. MPO 
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constitutes major component of neutrophil azurophilic granules and ELANE is 
involved in hydrolyzing proteins within azurophil granules. Here, it is shown that 
DNA methylation can underlie the regulation of bacterial containment. 
Furthermore, methylation changes were also found in the vicinity of TREM-2. A 
recent study identifies TREM-2 as a potential treatment target for septicemic 
melioidosis, whereby TREM-2 deficiency leads to decreased inflammation and 
reduced organ damage [198]. 
In summary, the work presented in this chapter supports the role of DNA 
methylation in regulating important drivers of the pathology of infectious 
disease. These results demonstrate the potential clinical relevance of 
incorporating epigenetics information to guide the understanding of the disease. 
Implementing a research framework that uses studies of epigenetics would no 
doubt maximize our ability to develop novel treatments for complex diseases.  
Whether the changes observed here are common to both septicemic 
melioidosis and sepsis caused by other infections awaits investigation. 
Moreover, it is crucial to assess the temporal changes over the course of 
infection and also relate to disease severity. The most robust findings may 
result from using longitudinally sampled cohorts of various infections 
distinguishing septicemic melioidosis from sepsis caused by other pathogens. 
This would no doubt contribute to the development of diagnostic assays.  
  
 112 
CHAPTER 4. HOST PATHOGEN INTERACTIONS AND METABOLISM 
 
4.1 Introduction 
Common virulence factors such as capsule, flagella, type III, V and VI 
secretion systems of B. pseudomallei have been widely investigated 
[121,199,200], however, the large genome of B. pseudomallei (7.2 Mbp) 
accommodates a range of metabolic pathways, which still remain unstudied in 
terms of their role in infection. In B. pseudomallei, an incomplete trehalose 
metabolism results in lower pathogenic potential [98]. This suggests a link 
between metabolism and virulence. 
The enzyme trehalase forms an important part of the trehalose pathway 
by converting trehalose into glucose. The trehalase gene has been classified as 
a potential virulence-associated gene in bacteria; Its presence in multiple 
pathogen species and absence in non-pathogenic bacteria have been 
demonstrated using computational comparative genomics [201]. B. 
pseudomallei is one of the pathogenic bacteria, which carry the trehalase gene 
(annotated as treA). Whole-genome tiling arrays with B. pseudomallei showed 
that treA is expressed in various physical, chemical, and biological conditions 
[202]. Vanaporn et al. [98] explored the role of trehalase on stress adaptation 
and virulence in B. pseudomallei. In the study of Vanaporn et al., a treA deletion 
mutant (ΔtreA) was constructed in B. pseudomallei K96243 strain. The wild type 
B. pseudomallei and B. pseudomallei ΔtreA were compared for growth, 
tolerance to thermal stresses, biofilm formation, ability to survive inside 
macrophages, and killing in the Galleria mellonella and mouse infection models.  
The growth of the wild type and the treA mutant was similar in M9 minimal 
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medium with glucose as the carbon source. However, in M9 minimal medium 
with trehalose as the sole carbon source the treA mutant failed to grow whereas 
the wild type strain grew. This showed that the trehalase enzyme (TreA) is 
active during growth in culture medium. The treA mutant had increased 
tolerance against heat and cold stress but produced less biofilm. Moreover, the 
treA mutant had reduced ability to proliferate in macrophages and to kill G. 
mellonella and mice. Thus, mutation in trehalase gives reduced virulence even 
though in treA mutant the heat/cold stress tolerance is increased. Tolerance to 
stresses can differ in different environments. The heat/cold stress tolerance is 
measured when the bacteria grow on a medium rather than in a host cell. 
Within the host, the interaction of bacteria with stress-associated chemicals can 
be different. This interaction will depend on the nutrient availability and the 
influence of host signals. While current experimental findings support an 
important role for trehalose metabolism in B. pseudomallei virulence, it is very 
difficult to design future experiments to investigate the B. pseudomallei 
metabolism within the host environment. Many of the experimental techniques 
allow taking measurement in bacterial culture, however it is challenging to apply 
these techniques to investigate the intracellular life style of bacteria. For 
example, measuring concentration changes of metabolic products of bacteria 
growing inside a host cell is not achievable especially for Biosafety Level 3 
bacteria such as B. pseudomallei. Therefore, in silico models are useful in 
studying the metabolic changes in highly pathogenic bacteria.  
A comprehensive understanding of the complex interplay of virulence 
and trehalose metabolism can significantly benefit from combining experiments 
with computational and mathematical reasoning. Studying the interactions 
between the components of the biological system is key to deciphering how 
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organisms and biological systems work. The organisation of the network of 
these interactions is not always straightforward. Mathematical modelling aids 
the interpretation of these nonlinear processes and thus unravels the systems 
behaviour. In fact, mathematical models of yeast trehalose metabolism have 
been constructed [203,204] and used to demonstrate that yeast regulates 
glycolysis, the central pathway in energy metabolism, via the trehalose pathway 
in order to adapt to dynamic changes in the carbon source [205].  
A study by van Heerden et al. [204] demonstrated that the trehalose 
pathway in yeast regulates the maintenance of functional glycolysis and 
facilitates the yeast to cope with stresses such as excess glucose availability. 
This study focused on the trehalose cycle formed by the TPS/TPP pathway 
(OtsA/OtsB in bacteria, Figure 4.1.1) and trehalase: In this cycle, trehalose 6-
phosphate (T6P) synthase (TPS) synthesizes T6P from glucose 6-phosphate 
(G6P), T6P is converted to trehalose by T6P phosphatase (TPP), trehalase 
converts trehalose to glucose, which is phosphorylated to G6P (the first step of 
yeast glycolysis) completing the cycle. In particular, cells with a defect in TPS 
were shown to accumulate glycolytic intermediates and these cells were not 
able to grow on excess glucose. Smallbone et al. [203] also used mathematical 
modelling to investigate the effects of knocking out TPS and quantified the 
resulting changes to metabolite concentrations.  The link between the TPS 
mutant and cellular growth has been known for a long time [206–208]. 
Therefore, previous mathematical modelling analyses of trehalose metabolism 
were limited to the TPS mutant.  
This chapter tests the hypothesis that the B. pseudomallei trehalase 
mutant may be less virulent due to impaired growth. Existing mathematical 
models of the trehalose pathway were implemented and modified for bacterial 
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cells to allow the in silico investigation of the trehalase mutant, with the aim of 
evaluating whether glycolysis is affected in the trehalase mutant. Furthermore, 
metabolic networks of B. pseudomallei were analysed at the genome scale to 
simulate growth under different conditions and predict the effects of gene 
knockouts. 
This chapter is organised as follows: the Methods section first discusses 
the modelling approaches for constructing metabolic pathways. The trehalose 
cycle was reviewed reaction by reaction. Knowledge of genes and the encoded 
enzymes of trehalose cycle were extracted from the literature and databases. 
Much of the kinetic information needed for constructing the trehalose cycle was 
obtained from articles with kinetic models of trehalose metabolism in yeast 
[203,209].  
 
 
4.2 Methods 
4.2.1 Mathematical modelling of metabolic pathways 
Mathematical models of metabolism have been developed using two 
major modelling methodologies. Metabolic models contain either contain a few 
reactions described to high kinetic detail (kinetic models), or a large set of 
reactions with little or no kinetic information (constraint-based models) [31].  
Kinetic models allow for dynamic simulations and control analysis. To 
build a kinetic model, rate laws need to be assigned to all reactions and the 
kinetic constants in each reaction must be determined. Extensive experimental 
data is required to characterize the mechanics of a kinetic model. For this 
reason, kinetic models are often available only for central pathways of well-
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studied model organisms, such as Escherichia coli or Saccharomyces 
cerevisiae [32,33].  
On the other hand, the increasing number of fully sequenced genomes 
allows the construction of constraint-based models for a wide range of 
organisms. Constraint-based models only account for the stoichiometry and 
directionality of reactions, which can be derived from genome annotations.  
As biological processes are complex large-scale systems, complete 
understanding of metabolic behaviour is a challenging task. Therefore, it is 
crucial to exploit the existing data belonging to the organism of interest such as 
genome sequencing or transciptomics as well as to utilise detailed established 
models, which are widely described and analysed in model organisms. As the 
trehalose pathway is extensively studied in yeast, kinetic information on 
individual reactions is available. Section 4.3.1 reviews the biology and the 
mathematical description of reactions in the trehalose cycle sourced from yeast 
kinetic models [203,204]. For every reaction, in order to adapt the model to B. 
pseudomallei, the presence or absence of genes encoding for the enzymes was 
assessed. As kinetic parameters on B. pseudomallei enzymes were not 
available in the literature and their measurements were beyond the scope of 
this thesis, models with yeast or E. coli kinetic parameters were used to study 
trehalose metabolism. Sequence similarity between the B. pseudomallei and 
yeast or E. coli genes/proteins were calculated to evaluate whether the use of 
such parameters was appropriate. 
 
4.2.2 The structure of the trehalose cycle 
Kinetic models of yeast [203,204] were available in SBML format, which 
is a common language for computer models of biological systems. For the 
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purposes of building a plausible model for B. pseudomallei trehalose 
metabolism, modifications were made to the reaction kinetics and interactions of 
the trehalose cycle (the structure is illustrated in Figure 4.2.1) based on existing 
knowledge on bacterial metabolism obtained from the literature (the resultant 
models are referred to as modified models in this thesis). These modifications 
are explained in detail in Section 4.3.  
 
 
Figure 4.2.1. A structural model of the trehalose cycle. Enzymes are in blue. 
Evidence of allosteric inhibition of hexokinase (hk) by T6P (trehalose 6-
phosphate) is found in yeast [207] (dotted line in green). G6P: glucose 6-
phosphate; G1P: glucose 1-phosphate; UDG: uridine diphosphate (UDP) 
glucose; F6P: fructose 6-phosphate; FBP: fructose 1,6-biphosphate; glk: 
glucokinase; pgi: glucose 6-phosphate isomerase; pfk: phosphofructokinase. 
The structure is drawn using information derived from the KEGG database [26].  
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Sequence and structural similarity are indicative of catalytic activity and 
substrate specificity of proteins [210]. To reconstruct the B. pseudomallei 
trehalose pathway using kinetic information from model organisms, the similarity 
of B. pseudomallei enzymes to E. coli or yeast enzymes was assessed. For 
this, DNA and protein sequences were retrieved from NCBI [211], the 
Burkholderia Genome Database [212], the Saccharomyces Genome Database 
[213], and EcoGene 3.0 [214]. Multiple sequence comparison was carried out 
using the Multiple Sequence Alignment tool Clustal Omega [215]. Sequences 
with >30% identity were considered homologous following a common rule of 
thumb [216]. Furthermore, the conserved domains in B. pseudomallei protein 
sequences were identified using NCBI’s Conserved Domain Database (CDD) 
[217]. Conserved domains provide insight into sequence, structure, and function 
relationships. E-values were recorded, which report the number of hits that can 
be expected to be seen by chance within the given location of the query 
sequence. E-values < 0.001 were considered significant [218].  
 
4.2.3 Kinetic modelling of the trehalose cycle  
Metabolic pathways consist of reactions, where reactants are converted 
into products at rates that depend on the concentrations of reactants, activators, 
inhibitors, and enzymes etc.  
Enzymes catalyse the conversion of substrates into products. They are 
highly specific and can be regulated by feedback systems to provide a precise 
control over the rate of a reaction. Enzymatic reactions are often described 
using Michaelis-Menten kinetics [219], in which the reaction rate v is given by  ! =  !!"#!!!!! Equation 1 
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where S is the substrate concentration, vmax is the maximum reaction rate, and 
KM represents the concentration of substrate for which the rate of reaction is 
half the maximum (vmax/2). 
Reaction networks can be formalized as ordinary differential equations, 
which represent the events of the simultaneously occurring reactions and tracks 
the effects on network components over time [220].  
The yeast SBML models (referred to as the Smallbone and van Heerden 
models in this thesis) [203,204] were implemented and modified in MATLAB. 
The MATLAB code was formulated to facilitate modification of parameters and 
initial conditions of the system. The MATLAB code was able to solve the 
differential equations representing the system for a given combination of 
parameters and initial conditions, where the general form of the differential 
equation is, 
!! = ! ! !,! ,        ! ! =  !! Equation 2 
Here, S is the stoichiometry matrix, metabolite concentrations are 
denoted by x, and the parameters (e.g. kinetic constants such as Km or vmax) by 
p. Given the structure of the network, the parameters and initial conditions (x0), 
time evolution of the variables (e.g. metabolite concentrations) can be 
calculated. Often the steady state values are of interest. A steady state is 
reached when the system is in equilibrium and the concentration of each 
reactant stays constant in time (x’=0). The computational condition used to 
identify a steady state was that the levels of the metabolites were constant – as 
assessed by an absolute tolerance value of 10-6 - in the last 10% of the 
simulation time.  
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4.2.4 Integration of transcriptomic data and mutants 
Chieng et al. [126] reported expression profiles of B. pseudomallei genes 
during intracellular growth in host macrophages relative to in vitro growth. 
During intracellular infection, numerous genes involved in metabolism were 
down-regulated. The fold change in expression of down-regulated genes 
involved in the trehalose cycle is listed in Table 4.2.1. 
 
Table 4.2.1 Trehalose metabolism related genes of B. pseudomallei that 
are down-regulated in host macrophages relative to in vitro growth [126].  
Gene Description 
Log2 Fold change (in 
vivo/in vitro) at the 
indicated time (h)  
1 2 4 6 
BPSL2410 otsA, alpha,alpha-trehalose-phosphate synthase -5.90 -3.11 -3.94 -2.89 
BPSL1981 galU, UTP--glucose-1-phosphate uridylyltransferase -7.91 -5.48 -7.52 -2.81 
BPSL1413 pgi, glucose-6-phosphate isomerase -6.75 -3.33 -4.43 -2.75 
 
 
In addition, genome wide transcriptome profiles of B. pseduomallei were 
available on the Pathosystems Resource Integration Center (PATRIC) 
Database [221]. This data included the B. pseduomallei transcriptome profiles 
obtained under exposure to 82 diverse physical, chemical, and biological 
conditions collected by Ooi et al. [202], and the growth transcriptome collected 
by Rodrigues et al. [222]. For this work, the experimental condition where the 
expression of B. pseudomallei genes in infected murine lungs were measured 
relative to in vitro growth were selected as there was a significant change in 
trehalase expression (|Log2 Ratio| >= 1). The fold changes are listed in Table 
4.2.2.   
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Table 4.2.2 Fold change in activity of trehalose metabolism related genes 
in B. pseudomallei in infected murine lungs relative to in vitro growth 
[202].  
Reaction Locus Tag Log2 Fold change  
Trehalase BPSS0671 1.16 
T6P phosphatase BPSL2411 0.25 
T6P synthase BPSL2410 -0.04 
Glucokinase BPSL2614 -0.13 
Glucose transport BPSL0498 -0.01 
Phosphoglucomutase BPSL2666 0.24 
UDP–glucose phosphorylase BPSL1981 -0.22 
G6P isomerase BPSL1413 1.05 
 
The response of B. pseudomallei during infection was simulated by 
multiplying the enzymatic activities by the factors listed in Table 4.2.1 and Table 
4.2.2. Furthermore, the effects of knocking out a gene (mutants) were simulated 
by reducing the genes activity to 1% of its normal level. Figure 4.2.2 
summarises the analysis pipeline, building the kinetic models and the 
incorporation of the gene activities.  
 
Figure 4.2.2 Analysis pipeline for the construction of kinetic model of the 
trehalose cycle and the integration of gene expression data 
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4.2.5 Sensitivity analysis 
Sensitivity analysis aids the evaluation of the effect of changing a 
parameter on the behaviour of the model.  
The sensitivities of the steady state metabolite levels with respect to 1% 
parameter perturbations were calculated using the following equation [34], !!,! =  ∆!!/!!∆!!/!!  ≈  (!!!!!!!)/!!(!.!" !!!!.!! !!)/ !!  = !!!!!!!!.!" !!            Equation 3 
Here xi is the nominal steady state metabolite level calculated using the 
unperturbed parameter values, xi+ and xi- are the steady state metabolite levels 
that are reached when the parameter value pj, is increased or decreased by 
1%, respectively. 
 
4.2.6 Genome-scale metabolic construction of B. pseudomallei and Flux 
Balance Analysis  
The metabolic network of B. pseudomallei K96243 was constructed 
using the Model Seed [223]. Flux balance analysis (FBA) was used to assess in 
silico growth of B. pseudomallei. FBA for maximizing growth can be described 
as: Maximize !!"#$%&& such that !" = 0 and !!"# ≤ v ≤  !!"# 
 
where S is the stoichiometry matrix (rows corresponding to metabolites and the 
columns to reactions) and v are fluxes (conventionally in units of mmol/gDW/h ) 
through each reaction and, !!"# !"# !!"# are lower and upper bounds of the 
fluxes, respectively. FBA finds a solution where all the fluxes are in equilibrium, 
i.e the steady state !" = 0 while optimising !!"#$%&& (the growth rate in units of 
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h−1). FBA simulations were conducted using the COBRA Toolbox in MATLAB 
[224]. 
4.3 Results and Discussion 
4.3.1 Reactions in the trehalose cycle 
4.3.1.1 Trehalase 
The trehalase deduced structures from bacterial, animal, plant, and fungi 
origin have been previously reported to be highly conserved in spite of having 
marked differences in amino acid sequences suggesting an evolutionary 
pressure to maintain the trehalose degradation function [225]. A single 
trehalase encoding gene (BPSS0671) has been identified in B. pseudomallei. 
The B. pseudomallei trehalase was similar to the E. coli periplasmic trehalase 
treA with 56.89% DNA sequence identity and 53.76% protein sequence identity 
(Table 4.3.1). In addition, E. coli has a cytoplasmic trehalase (TreF) and 3 other 
trehalase related proteins: TreB, TreC, TreR. Conserved domain search 
identified a neutral trehalase domain (TreA) (Table 4.3.2) supporting the 
presence of trehalase activity in carbohydrate transport and metabolism in B. 
pseudomallei. The B. pseudomallei trehalase was similar to S. cerevisiae 
neutral trehalase NTH1 (36.98% DNA sequence identity, 27.85% protein 
sequence identity; Table 4.3.1). Additionally, S. cerevisiae has an acid 
trehalase encoded by ATH1, and a neutral trehalase NTH2, which does not 
encode a trehalase activity. 
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Table 4.3.1. Trehalase sequence comparison. Sequence comparison was 
carried out using Clustal Omega. The sequence for each gene / protein is 
compared to B. pseudomallei threalase [BPSS0671 Burkholderia pseudomallei 
K96243.]  
 
 
Table 4.3.2. NCBI CD-Search engine predicted domains for TreA protein. 
Conserved domains identified in the protein sequences of B. pseudomallei 
trehalse. 
 
 
 
4.3.1.2 T6P phosphatase and T6P synthase 
Trehalose biosynthesis through the trehalose-6-phosphate synthase 
(TPS) - trehalose-phosphatase (TPP) route is the most widely distributed 
pathway across kingdoms [106]. While bacteria have five biosynthetic pathways 
known for trehalose, yeast has only two, with the TPS/TPP pathway being the 
main pathway. In this two-step process, glucose 6-phosphate and UDP-glucose 
are converted by TPS (encoded by TPS1 in yeast, encoded by otsA in bacteria) 
into trehalose 6-phosphate, which is then converted with water into trehalose 
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and phosphate by TPP (encoded by TPS2 in yeast, encoded by otsB in 
bacteria). In yeast, the TPS/TPP pathway received wide attention as the 
intermediate metabolite trehalose 6-phosphate can affect glycolysis by inhibiting 
hexokinase, which is the enzyme involved in the first step of glycolysis [226].  
This is reviewed next, in Section 4.3.1.3. Sequence comparison showed that B. 
pseudomallei trehalose-phosphatase is similar to E. coli and S. cerevisiae 
trehalose-phosphatase (Table 4.3.3). CD-Search confirmed the presence of 
Trehalose-6-phosphatase (OtsB) activity in B. pseudomallei trehalose-
phosphatase protein (Table 4.3.1). Two genes were identified in B. 
pseudomallei for trehalose-phosphate synthase: BPSL2410 and BPSL1044. 
These two B. pseudomallei trehalose-phosphate synthases exhibit high 
homology (70.10% DNA sequence identity and 61.72% protein identity) and 
were similar to E. coli OtsA and S. cerevisiae TPS1, respectively (Table 4.3.5 
and Table 4.3.6). CD-Search was conducted on the protein sequence encoded 
by BPSL2410 and the results showed OtsA activity (Table 4.3.7)          
Table 4.3.3. Trehalose-phosphatase sequence comparison (otsB). 
Sequence comparison was carried out using Clustal Omega. The sequence for 
each gene / protein is compared to B. pseudomallei trehalose-phosphatase 
[BPSL2411 otsB trehalose-phosphatase cytoplasmatic] 
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Table 4.3.4. NCBI CD-Search engine predicted domains for OtsB protein. 
Conserved domains identified in the protein sequences of B. pseudomallei 
trehalose-phosphatase. 
 
Table 4.3.5. Trehalose-phosphatase sequence comparison (otsA). 
Sequence comparison was carried out using Clustal Omega. The sequence for 
each gene / protein is compared to B. pseudomallei threalase [BPSL2410 
alpha,alpha-trehalose-phosphatase synthase Cytoplasmatic] 
 
 
Table 4.3.6. Trehalose-phosphatase sequence comparison (otsA UDP-
forming). Sequence comparison was carried out using Clustal Omega. The 
sequence for each gene / protein is compared to B. pseudomallei threalase 
[BPSL1044 alpha,alpha-trehalose-phosphatase synthase Cytoplasmatic] 
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Table 4.3.7. NCBI CD-Search engine predicted domains for OtsA protein. 
Conserved domains identified in the protein sequences of B. pseudomallei 
trehalose-phosphate synthase. 
 
 
4.3.1.3 Glucokinase 
The first step in metabolising intracellular glucose involves 
phosphorylation of glucose to form glucose 6-phosphate. In yeast, this reaction 
can be catalysed by three enzymes: hexokinases (HXK1 and HXK2), and 
glucokinase (GLK1) [227]. The trehalose pathway can regulate yeast glycolysis 
via T6P acting as a competitive inhibitor of hexokinases to glucose; the 
regulation is mainly through the inhibition of hexokinase II, while no inhibition is 
observed upon glucokinase [207]. 
In most bacteria, glucose is transported by the phosphotransferase 
system (PTS) as glucose-6-phosphate [228]. Therefore, glucokinase is not used 
in the utilisation of extracellular glucose. For this reason, the glucokinase 
reaction is not included in bacterial kinetic models, which focus on the central 
metabolism such as glycolysis. However, in metabolism of disaccharides such 
as lactose, maltose, or trehalose, glucokinase has an important role of 
phosphorylating the glucose formed inside the cell. 
Glucokinase and hexokinases differ in their kinetic properties. 
Glucokinase has a lower affinity (high Km) for glucose than the other 
hexokinases and therefore is effective only when glucose is abundant [229]. 
Glucokinase is not inhibited by its product, glucose-6-phosphate; the rate of 
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reaction is driven by the supply of glucose, not by the demand for end products 
[230]. 
Meyer et al. reported the kinetic properties of glucokinase in E. coli [230]. 
In yeast, hexokinase is modelled to allow for the competitive inhibition of 
glucose by T6P. Here, in the modified model, this step is modelled following the 
kinetics of glucokinase [230]. 
 
Table 4.3.8. Glucokinase sequence comparison. Sequence comparison was 
carried out using Clustal Omega. The sequence for each gene / protein is 
compared to B. pseudomallei threalase [Glk BPSL2614 bifunctional 
glucokinase/RpiR family transcriptional regulator Cytoplasmatic] 
 
 
Table 4.3.9. NCBI CD-Search engine predicted domains for OtsA protein. 
Conserved domains identified in the protein sequences of B. pseudomallei 
glucokinase. 
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Table 4.4.10 summarises the rate laws used in the kinetic model of the 
trehalose cycle. These rate laws have been adapted from the Smallbone Model 
[203]. Smallbone et al. retrieved much of the kinetic information from a series of 
publications [231–234]. In the Smallbone Model, the conversion of glucose to 
glucose 6-phosphate is modelled with hexokinase kinetics allowing for the 
competitive inhibition of glucose by trehalose 6-phosphate. In this chapter, in 
the Modified Smallbone Model, the hexokinase reaction is replaced with the 
glucokinase reaction for the reasons explained in Section 4.3.1.3. The resulting 
rate law is presented in Table 4.3.10. 
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Table 4.3.10. Reaction laws for each step of the trehalosecycle for the 
Modified Smallbone Model. 
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4.3.2 Response of yeast kinetic model (Smallbone Model) to stress 
conditions and mutation  
The kinetic model of the trehalose cycle in yeast developed by 
Smallbone et al. [203] investigated the effects of heat shock, osmotic shock, 
and the TPS1 mutation on the concentrations of metabolites directly involved in 
trehalose metabolism. In this section, firstly, the simulation results demonstrated 
by Smallbone et al. were verified. This allowed testing of the model and to avoid 
any errors in translating the SBML file into MATLAB code. The steady state 
concentrations of the metabolites in response to heat shock and TPS1 mutation 
generated by Smallbone et al. [203], are shown in columns 2 and 4 of Table 
4.3.11. These values were successfully reproduced (column 3 and 5 of Table 
4.3.11) by simulating the response of the metabolites to heat shock and TPS1 
mutation (Figure 4.3.1 A and Figure 4.3.1 C). The system takes a longer time to 
reach the steady state in the TPS1 mutant compared to heat and osmotic shock 
(Figure 4.3.1). This shows that the system can tolerate heat and osmotic shock 
using the trehalose cycle. However, when the trehalose cycle is impaired (TPS1 
mutant), the system is imbalanced for a longer time. This can have adverse 
effects on the yeast cell.  
In addition, the trehalase mutant was simulated in the yeast model 
(Figure 4.3.2) by reducing the trehalase activity to 1% of its normal level; in this 
case trehalose accumulates and the system cannot reach equilibrium 
(simulations are carried out for a long time (10^50 min) to show that trehalose 
levels keep building up to biologically implausible levels ∼10^30 mM; Figure 
4.3.2B). 
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Table 4.3.11. Smallbone Model concentrations in response to heat shock, 
osmotic shock and, TPS1 mutation and trehalase mutation.  
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A
 
B 
C
 
Figure 4.3.1. Smallbone Model concentrations in response to (A) heat 
shock, (B) osmotic shock, (C) TPS1 mutation. Initial concentrations and 
parameters were taken from Smallbone et al. [203]. Changes in enzymatic 
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activities induced by heat and osmotic shock were taken from Smallbone et al. 
[203]. TPS1 mutation was simulated by reducing TPS1 activity to 1% of the 
normal level.  
 
A 
 
B 
 
Figure 4.3.2. Trehalase mutation in yeast. Smallbone Model 
concentrations in response to trehalase mutation (Trehalase activity is 
reduced to 1% of its normal level). Initial concentrations and parameters were 
taken from Smallbone et al. [203]. (A) simulation time 5x104 (B) simulation time 
1035. 
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4.3.3 Response of the Smallbone Modified Model to stress conditions and 
mutation  
The model was modified by replacing the hexokinase kinetics with 
glucokinase kinetics as explained in Section 4.3.1.3 (the new model is referred 
to as Smallbone Modified Model). As this has introduced a change to the 
system, a simulation was carried out to restore the system into a new 
equilibrium (Figure 4.3.3). The steady state values that were reached in this 
simulation were accepted as initial conditions for the subsequent simulations 
when the Smallbone Modified Model was used.   
 
 
Figure 4.3.3. Modified Smallbone Model simulated using initial condition 
data of yeast (as used in the original Smallbone Model). Steady state values 
that are reached in this simulation are taken as the initial concentrations of 
Smallbone Modified Model in subsequent analyses.  
 
The response of the modified model to heat shock (Figure 4.3.4), 
osmotic shock (Figure 4.3.5), TPS1 mutation (Figure 4.3.6), and trehalase 
mutation (Figure 4.3.7), was compared to the response of the original yeast 
model. Similar trends were observed (i.e. increase or decrease in the metabolite 
concentration, accumulation of trehalose in trehalase mutant), apart from the 
Time (min)
0 0.05 0.1 0.15 0.2 0.25 0.3 0.35 0.4 0.45 0.5
Co
nc
en
tra
tio
n 
(m
M
)
10-2
10-1
100
101
 
Trehalose
Glucose
G6P
G1P
UDG
T6P
 136 
concentration of UDG during heat shock, which is increased in the modified 
model and decreased in the yeast model. Table 4.3.12 lists the fold changes in 
concentration in the modified model.  
 
 
Figure 4.3.4. Metabolite concentrations in response to heat shock. 
Smallbone Model is marked in blue. Smallbone Modified Model is marked red. 
Changes in enzymatic activities induced by heat shock were taken from 
Smallbone et al. [203]. 
 
 
Figure 4.3.5. Metabolite concentrations in response to osmotic shock. 
Smallbone Model is marked in blue. Smallbone Modified Model is marked red. 
Changes in enzymatic activities induced by osmotic shock were taken from 
Smallbone et al. [203]. 
 
Time (min)
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
Co
nc
en
tra
tio
n
(m
M
)
0
0.05
0.1
0.15
0.2 Trehalose
Time (min)
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
Co
nc
en
tra
tio
n
(m
M
)
0
0.5
1
1.5
2 Glucose
Yeast Model Modified Model
Time (min)
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
Co
nc
en
tra
tio
n
(m
M
)
0
5
10
15 G6P
Time (min)
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
Co
nc
en
tra
tio
n
(m
M
)
0.09
0.1
0.11
0.12
0.13
0.14 G1P
Time (min)
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
Co
nc
en
tra
tio
n
(m
M
)
0.6
0.65
0.7
0.75
0.8 UDG
Time (min)
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
Co
nc
en
tra
tio
n
(m
M
)
0.015
0.02
0.025 T6P
Time (min)
0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 1.8 2
Co
nc
en
tra
tio
n
(m
M
)
0.04
0.05
0.06
0.07
0.08 Trehalose
Time (min)
0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 1.8 2
Co
nc
en
tra
tio
n
(m
M
)
0
0.5
1
1.5
2 Glucose
Time (min)
0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 1.8 2
Co
nc
en
tra
tio
n
(m
M
)
0
5
10
15
20
25 G6P
Time (min)
0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 1.8 2
Co
nc
en
tra
tio
n
(m
M
)
0.02
0.04
0.06
0.08
0.1 G1P
Time (min)
0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 1.8 2
Co
nc
en
tra
tio
n
(m
M
)
0.2
0.3
0.4
0.5
0.6
0.7
0.8 UDG
Time (min)
0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 1.8 2
Co
nc
en
tra
tio
n
(m
M
)
0.005
0.01
0.015
0.02 T6P
Yeast Model Modified Model
 137 
 
 
Figure 4.3.6. Metabolite concentrations in response to TPS1 mutantion. 
Smallbone Model is marked in blue. Smallbone Modified Model is marked red. 
TPS1 mutation was simulated by reducing TPS1 activity to 1% of the normal 
level. 
 
 
 
 
Figure 4.3.7. Metabolite concentrations in response to trehalase mutation. 
Smallbone Model is marked in blue. Smallbone Modified Model is marked red. 
Trehalase mutation was simulated by reducing trehalase activity to 1% of the 
normal level. 
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When the trehalase activity was reduced to 1% of its normal level (Figure 
4.3.7), representing the trehalase mutant, the system cannot reach equilibrium. 
A functioning trehalose cycle is necessary to stabilise the system. When the link 
between the trehalose and glucose is impaired, trehalose accumulates. 
Accumulation of trehalose can be harmful for the cell.  A simulation was carried 
out, where the trehalase activity was reduced to 10% of its normal level. This 
can represent a significant down-regulation of the trehelase gene. The system 
was stable with a significant increase in trehalose concentration (Figure 4.3.8). 
 
 
Figure 4.3.8. Smallbone Modified Model metabolite concentrations in 
response to down-regulation of trehalase (Trehalase activity is reduced to 
10% of the normal level). 
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Table 4.3.12. Simulated fold change in the Smallbone Modified Model 
concentrations in responses to heat shock, osmotic shock, TPS1 
mutation, and trehalase mutation. The values shown correspond to 
log10([X]ss/[x]0), where [X]ss is the steady state metabolite concentration and [X]0 
is the initial metabolite concentration. 
 
 
 
As reviewed in Section 4.2.4, genes such as trehalase and trehalose-
phosphate synthase were found to be differentially regulated during infection 
[126,202]. The change in the encoding gene expressions (Table 4.2.1 and 
Table 4.2.2) were incorporated to the model and used to estimate the change in 
the activities of the enzymes to evaluate the metabolite concentrations in 
response to infection. Table 4.3.13 summarises the changes in metabolite 
concentrations in each condition.  
 
Table 4.3.13. Simulated fold change in the Smallbone Modified Model 
concentrations in responses to infection. The values shown correspond to 
log10([X]ss/[x]0), where [X]ss is the steady state metabolite concentration and [X]0 
is the initial metabolite concentration. 
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The up-regulation of trehalase in infected murine lungs, results in slight down-
regulation of the upstream metabolites (trehalose and trehalose 6-phosphate) 
and slight up-regulation of Glucose 1-phosphate (Figure 4.3.9). 
 
 
Figure 4.3.9.   Change in Smallbone Modified Model concentrations in B. 
pseudomallei in infected murine lungs relative to in vitro growth.  
 
During the first hour of infection in host macrophages, the system is not in 
equilibrium as glucose 6-phosphate and glucose 1-phosphate accumulate 
(Figure 4.3.10). 
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Figure 4.3.10. B. pseudomallei during intracellular growth in host 
macrophages relative to in vitro growth 1h 
 
Substantial decrease in trehalose and trehalose 6-phosphate were 
observed in B. pseudomallei during 2h, 4h, and 6h in host macrophages (Figure 
4.3.11).  
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Figure 4.3.11. Change in Smallbone Modified Model concentrations in B. 
pseudomallei during intracellular growth in host macrophages relative to 
in vitro growth (A) 2h; (B) 4h; (C) 6h.   
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4.3.4 Sensitivity Analysis 
Section 4.3.3 demonstrated the response of metabolite concentrations to 
mutation, stress, or infection. During mutation, the activity of the corresponding 
reaction was abolished. During infection, the activities of corresponding 
reactions were affected with the changes in gene expression. Stress survival 
and adaptation to the environmental changes can require regulation of various 
parts of the metabolic process. This regulation can be different in different 
organisms. Due to the complex organisation of metabolic networks, it is not 
straightforward to tell which metabolites will be affected when a parameter is 
changed. A sensitivity analysis was performed to determine how every single 
parameter in the model could impact the level of metabolites. In Figure 4.3.12, 
the sensitivities for the original and modified Smallbone models were plotted. 
The concentration of trehalose is sensitive to the parameters of the trehalase 
reaction. Thus a mutation in trehalase enzyme can significantly alter the 
trehalose levels in the cell. When the parameter of a reaction is changed, the 
levels of the substrates of that reaction are affected. Sensitivities are similar in 
the original and modified Smallbone Model with the exception of glucose; 
unsurprisingly glucose is more sensitive in the original model to changes in 
glucose import, hexokinase, T6P synthase and T6P synthase phosphatase 
because of the inhibitory effect of T6P on glucose consumption included in the 
original model. However, glucose 6-phosphate exhibited low sensitivity to small 
perturbations in T6P-related reaction parameters, though previous simulations 
showed an increase in glucose 6-phosphate concentration when these 
parameters were altered significantly (e.g. Figure 4.3.1A). The efficacy of 
hexokinase inhibition by T6P was challenged previously [226,235], postulated 
to be significant in a narrow metabolic range and only relevant in a glucose 
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pulse. Next, in Section 4.3.5 a kinetic model of glycolysis was studied to provide 
a better understanding of the role of the trehalose metabolism and its 
interactions with glycolysis.  
 
 
Figure 4.3.12. Smallbone and Modified Model sensitivity statistics of the 
steady states with respect to 1% parameter perturbations. The Smallbone 
Model is referred to as ‘Model 1’ and the Modified Smallbone Model is referred 
to as ‘Model 2’. The rows correspond to the parameters, and the columns to 
metabolites. The colours (and the values on the cells) represent the sensitivity 
of the metabolite for the given parameter (calculated as explained in Section 
4.2.5). Metabolites: GLC, glucose; G1P, glucose 1-phosphate; G6P, glucose 6-
phosphate; TRH, trehalose; T6P, trehalose 6-phosphate; UDG, UDP-glucose. 
Parameters: ugp, UDP glucose phosphorylase; nth, trehalase; tps, T6P 
synthase; tpp, T6P phosphatase; hxk, hexokinase/glucokinase; hxt, glucose 
transport pgi, G6P isomerase; shock parameters represent the effect of change 
in the activity of the associated reaction.  
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4.3.5. Interaction of the trehalose cycle with glycolysis 
Van Heerden et al. [204] demonstrated that the trehalose cycle in yeast 
helps maintain functional glycolysis and facilitates yeast in coping with stresses 
such as excess glucose availability. In yeast, on excess glucose, the flux 
through the upper glycolysis pathway (ATP-consuming) is greater than the flux 
through the lower glycolysis pathway (ATP-generating). This imbalance can 
impair growth. Figure 4.3.13 illustrates the upper- and lower glycolysis and the 
trehalose cycle forming a feedback loop to the upper glycolysis pathway by 
inhibiting the synthesis of glucose-6-phosphate (inhibition of hexokinase by T6P 
as discussed in previous sections). This feedback was found to prevent the 
accumulation of the intermediates of the upper-glycolysis pathway and maintain 
the normal functional state of glycolysis. Mutants with a defect in the trehalose 
cycle can end up in an imbalanced state, resulting in metabolic malfunctioning. 
An alternative mechanism through which the trehalose cycle can ensure the 
proper functioning of glycolysis is to recover phosphate when needed. The 
trehalose cycle, as illustrated in Figure 4.2.1, produces phosphate during 
synthesis of UDP-glucose and trehalose.  
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Figure 4.3.13. The trehalose cycle and glycolysis in yeast. Figure adapted 
from [204] 
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This section first reviews the wild type and TPS1 mutant behaviour of the 
van Heerden Model. The results published by van Heerden et al. were 
reproduced and the analysis is expanded to include the trehalase mutant.  
Van Heerden et al. adapted the yeast kinetic glycolysis model of Teusink 
et al. [32] and introduced modifications that represents the interactions of the 
trehalose cycle with glycolysis. Of note, the trehalose cycle reactions are not 
defined explicitly. Instead, as the magnitude of change in G6P was found to be 
similar to that of T6P and trehalose [236], G6P levels were used to model the 
T6P inhibition and the flux from trehalose toward glycolysis, via.   ! !6!!" = !1− !2− !3+ !4  
In the above f1 is the flux through the hexokinase reaction and the rate equation 
of hexokinase (Equation ) includes a term for the T6P inhibition of hexokinase 
(highlighted in yellow; Ki,G6P, T6P inhibition constant of hk)  
 
!!! = !!"#,!! !"#!!"# !"#$!!"#$  −  !"#!!",!!!!"# [!6!]!!"#$1+ !"#!!"# + !"#!!"# 1+ [!6!]!!,!!! + [!6!]!!!! [!"#$]!!"!"   
 
f2 is the flux towards F6P; f3 is the flux towards glycogen;  
and f4 is the flux feeding to glycolysis from trehalose represented as !!"#!!"#$% ∗!6!.  
Furthermore, as the trehalose cycle was postulated to function as a 
phosphate recovery mechanism, phosphate was included as a free variable in 
the model. Whether the balanced state is reached depends on the initial 
concentration of the metabolites. When the initial concentration of phosphate is 
10.4 mM, the system reaches a steady state (Figure 4.3.14A). The difference in 
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rate between the upper and lower glycolysis pathways is zero (Figure 4.3.14B). 
Thus, there is no accumulation of metabolites and the system is in a balanced 
state.  
A
 
B 
 
Figure 4.3.14. Van Heerden Model simulated with initial Phosphate (Pi) 
level of 10.4 mM. FBP, fructose 1,6-biphosphate; ATP, adenosine 5’-
triphosphate; Pi, cytosolic phosphate; vp, the vacuolar import rate of Pi; vupper, 
the rate of upper glycolysis; vlower, the rate of lower glycolysis. (A) Metabolite 
concentrations reaching steady state. (B) The vacuolar import rate of Pi (vp) 
reaches zero at steady state. The rate between upper and lower glycolysis 
(vupper – vlower) reaches zero. These simulations reproduce Fig. 4 (C and E) in 
van Heerden et al. [209].  
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When the initial concentration of phosphate is 9.4 mM, the glycolytic 
intermediate fructose 1,6-bisphosphate (FBP) is accumulates (Figure 4.3.15 A). 
Upper glycolysis is faster than lower glycolysis and vacuolar transport of 
phosphate is not at steady state (Figure 4.3.15B). This imbalance impairs ATP 
generation and growth. This shows that phosphate dynamics are a key feature 
of the network. 
A 
 
B 
 
Figure 4.3.15. Van Heerden Model simulated with an initial phosphate (Pi) 
level of 9.4 mM. FBP, fructose 1,6-biphosphate; ATP, adenosine 5’-
triphosphate; Pi, cytosolic phosphate; vp, the vacuolar import rate of Pi; vupper, 
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the rate of upper glycolysis; vlower, the rate of lower glycolysis. (A) Metabolite 
concentrations resulting in imbalance (FBP accumulation and low ATP and Pi 
levels). (B) The vacuolar import rate of Pi (vp) and the rate between upper and 
lower glycolysis (vupper – vlower) is positive. These reproduce Fig. 4 (D and F) in 
van Heerden et al. [209].  
 
The imbalanced and the balanced state also depend on the feedback 
from T6P (trehalose 6-phosphate) to hexokinase (hxk). In the wild type there is 
no accumulation of metabolites (Figure 4.3.16).  
 
Figure 4.3.16. Simulated wild type metabolite concentrations in the van 
Heerden Model.  
 
When the feedback on hk is eliminated and the rate constant of trehalose 
branch is set to zero, representing the TPS1 mutant as defined by van Heerden 
et al., FBP accumulates while ATP and phosphate are depleted (Figure 4.3.17).  
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Figure 4.3.17. Metabolite concentrations in van Heerden Model in TPS1 
mutation. TPS1 mutation (as defined by van Heerden et al.) is simulated by 
eliminating the feedback on hexokinase and setting the trehalose branch flux to 
zero.  
 
In simulations, van Heerden et al. characterised the TPS1 mutant with 
the complete malfunction of the trehalose cycle, as all interactions between the 
trehalose cycle and glycolysis were eliminated to simulate the mutant 
phenotype (combined elimination of trehalose cycling and T6P-mediated 
feedback on hexokinase).  
In this section, the effects of eliminating the feedback on hexokinase and 
eliminating the trehalose branch were considered separately. To mimic a 
trehalase mutation, the rate constant of the trehalose branch was set to zero, 
while the feedback on hexokinase was kept intact. In this case, proper glycolytic 
functioning was established, as shown in Figure 4.3.18 - no accumulation of 
metabolites was observed.  
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Figure 4.3.18. Trehalase mutation. Simulated metabolite concentrations in 
the van Heerden Model under trehalase mutation (the trehalose branch 
flux was set to zero 
 
Next, a simulation was conducted in which the T6P-mediated feedback 
on hexokinase was eliminated and trehalose cycling was allowed. Trehalose 
cycling alone resulted in a functional glycolysis, where all metabolites were 
balanced and the phosphate level was recovered (Figure 4.3.19). 
 
 
Figure 4.3.19. Simulated model concentrations in the van Heerden Model, 
when the feedback on hexokinase is eliminated.) 
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The simulations show that balance in glycolysis is affected only when the 
trehalose cycle is shut down completely. As discussed in Section 4.3.1, in 
bacteria, the reaction from glucose to glucose 6-phosphate is mediated by 
glucokinase, for which no T6P mediated inhibitory effects were observed. As 
this aspect of trehalose metabolism is likely to be absent in bacteria, eliminating 
the trehalose cycling alone (trehalase mutant) can result in malfunctioning of 
bacterial glycolysis.  
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4.4 Genome-scale metabolic network of B. pseudomallei K96243 
In B. pseudomallei, reactions around trehalose are not limited to the ones 
in the trehalose cycle. Deciphering interactions, which B. pseudomallei 
trehalose may possess, is crucial for a complete understanding of the trehalase 
mutation. As the genome of B. pseudomallei is completely sequenced, 
metabolic networks of B. pseudomallei can be analysed at the genome scale to 
identify molecular links to trehalose.  
B. pseudomallei K96243 is the first sequenced strain of B. pseudomallei 
[121]. The reference genome is 7,247,547 bp in size consisting of two 
chromosomes of 4,074,542 bp and 3,173,005 bp. Using the genomic data 
available, the metabolic network of B. pseudomallei K96243 was constructed 
using Model Seed [223]. The model contains a biomass reaction, which is used 
as an estimate of growth. A summary of the model is presented in Table 4.4.1.  
 
Table 4.4.1. Summary of the B. pseudomallei K96243 genome-scale 
metabolic model. 
 
Organism  Burkholderia pseudomallei K96243 
Model ID Seed272560.3 
Class Gram negative 
Genome size  7,247 KB 
Model genes / Genes in genome  1,182 / 5,819 
Reactions with genes 1,314 
Exchange reactions 125 
Compounds 1,143 
Number of compounds in biomass 
reaction 
81 
  
 
To identify the reactions around trehalose in B. pseudomallei, the 
metabolites that are directly connected to trehalose were identified. This 
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subnetwork was extended by adding the connecting reactions and main 
reactions in glycolysis; the network structure is illustrated in Figure 4.4.1.  
 
 
 
 
Figure 4.4.1. Subnetwork of the B. pseudomallei genome-scale metabolic 
model. Green area: extracellular compartment. Purple rectangles: metabolites. 
Diamonds: reactions. 
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Nine different simulations were run in which the maximum uptake rates 
of glucose and trehalose were changed on the defined minimal media 
composition required for growth. Negative values for the given carbon source 
means an intake to the cell.  
 
Biomass increased with an increasing concentration of glucose. The 
system was also able to grow on trehalose as there exists a trehalose uptake 
mechanism in the model. Although a few mechanisms have been suggested 
(e.g using periplasmic trehalose to convert trehalose into glucose followed by 
phosphotransferase-mediate glucose uptake [98]), the exact mechanisms of 
trehalose uptake are not fully understood.  
 
Table 4.4.2. Growth simulations of the genome-scale metabolic model in 
different media compositions.  
 
Simulation D-Glucose Trehalose Biomass 
sim1 -10 0 1.307 
sim2 -50 0 6.5349 
sim3 -100 0 13.0698 
sim4 -1000 0 69.6929 
sim5 0 0 4.69E-13 
sim6 -10 -10 3.9209 
sim7 -10 -100 27.4465 
sim8 0 -10 2.614 
sim9 0 -100 26.1395 
 
For each simulation, the fluxes were mapped in the subnetwork using the 
color-coding explained in Figure 4.4.2. Positive and negative values for fluxes 
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determine the direction of flux in a reversible reaction (denoted by a double 
arrow). As an example, in Figure 4.4.3 the reaction “EX D_Glucose”, which is 
the uptake reaction of glucose, is a reversible reaction. It is coloured green in 
this simulation, hence the flux is in the opposite direction the (it is towards “D-
Glucose”. 
 
 
Figure 4.4.2. Color-coding scheme used to represent fluxes in the flux 
maps shown in Figures 4.4.3-4.4.7. When the value is positive, the flux goes 
in the same direction as the arrow on the pathway figures (yellow – low flux 
rate; red – high flux rate). When the value is negative, the flux goes in the 
opposite direction to the arrow (green – low flux rate; blue – high flux rate). 
White, no flux. 
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Figure 4.4.3. Sim 1. Subnetwork of the B. pseudomallei genome-scale 
metabolic model. Distribution of fluxes during growth in glucose: -10. The 
fluxes are represented using the color-coding scheme in Figure 4.4.2. 
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Figure 4.4.4. Sim 4. Subnetwork of the B. pseudomallei genome-scale 
metabolic model. Distribution of fluxes during growth in Glucose: -1000. The 
fluxes are represented using the color-coding scheme in Figure 4.4.2. 
 
The flux maps (Figure 4.4.3 and Figure 4.4.4) show that as more glucose 
is available, more flux is going through certain reactions. However no flux is 
going through the trehalose cycle. The system optimizes biomass production 
and hence prefers direct routes leading to biomass precursors. For this, the 
trehalose cycle is not an efficient path for the system. 
The flux maps in Figure 4.4.5 and Figure 4.4.6 show that the trehalase 
reaction doesn’t carry flux even when there is trehalose available as the carbon 
source. Different objective functions can provide different flux distributions [237]. 
 160 
To demonstrate that the trehalose cycle can carry flux, a test objective function 
was generated, which optimises the production of trehalose. Under this 
condition, the trehalase reaction was indeed able to carry flux (Figure 4.4.7). 
This attests that, with formulating relevant objective functions, the model can be 
used to study fluxes around trehalose. Under stress conditions such as a heat 
shock, the cell might need to produce more trehalose.    
 
 
Figure 4.4.5. Sim 6. Subnetwork of the B. pseudomallei genome-scale 
metabolic model. Distribution of fluxes during growth in glucose: -10 and 
Trehalose: -10. The fluxes are represented using the color-coding scheme in 
Figure 4.4.2. 
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Figure 4.4.6. Sim 9. Subnetwork of the B. pseudomallei genome-scale 
metabolic model. Distribution of fluxes during growth in trehalose: -100. The 
fluxes are represented using the color-coding scheme in Figure 4.4.2. 
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Figure 4.4.7. Subnetwork of the B. pseudomallei genome-scale metabolic 
model. Distribution of fluxes Flux distribution when trehalose is added to the 
objective function. The fluxes are represented using the color-coding scheme in 
Figure 4.4.2. 
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4.5 Functional analysis of the genome-scale metabolic network of 
Burkholderia pseudomallei K96243 and gene essentiality 
The functions of the genes present in the model were analysed using the 
annotations available in Burkholderia Genome Database [212]. The genes were 
assigned a specific functional description using the Clusters of Orthologous 
Groups (COG) annotation. These functional descriptions are associated with 
more general category letters. The general categories were used to give an 
overview of the functional distribution of the genes (Fig 4.5.1). The majority of 
the genes were associated with metabolic functions such as amino acid 
(22.3%), coenzyme (10.2%), carbohydrate (7.7%) transport and metabolism.  
 
 
Figure 4.5.1. Functional distribution of genes (n = 1182) present in the 
genome-scale metabolic model of Burkholderia pseudomallei K96243, 
SEED272560_3. The genes were assigned a specific functional description 
using the Clusters of Orthologous Groups (COG) database. These functional 
descriptions are associated with general category letters. 
 
To identify the essential bacterial genes required for bacterial growth, 
over 106 transposon insertion mutants were screened by Moule et al. using 
TraDIS [238]. TraDIS experiments were performed in Luria-Bertani (LB) broth or 
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agar at 37°C. Genes with no or few insertion sites were predicted to be 
essential. This resulted in 505 Burkholderia pseudomallei K96243 genes 
predicted to be essential for in vitro growth and survival. Although Moule et al. 
provided a functional analysis of the essential genes, for consistency with the 
previous functional analysis in Figure 4.5.1, the COG category distribution of 
these experimentally predicted essential genes were determined. The results 
were consistent with the Gene Ontology analysis presented in the study. The 
majority of the genes were associated with metabolic functions such as energy 
production, amino acid-, carbohydrate-, nucleic acid metabolisms (Figure 4.5.2).  
 
 
Figure 4.5.2. Functional distribution of essential genes predicted using 
TRADIS. The genes were assigned a specific functional description using the 
Clusters of Orthologous Groups (COG) database. These functional descriptions 
are associated with general category letters. The majority of genes were 
associated with metabolic functions. Other essential functions are translation, 
transcription, and transport.  
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Out of these 505 genes, 211 genes were present in the genome-scale 
model of Burkholderia pseudomallei K96243 SEED272560_3. Functional 
analysis was performed on the remaining 294 genes, to see whether there are 
any metabolic genes (Figure 4.5.3). 75 metabolic genes were found. The 
specific functionality of these genes are to be assessed and the genes can be 
potentially added to the metabolic model. The rest of the genes can be 
virulence factors providing an advantage to the pathogen in diverse 
environments such as in a host. However, these are less likely to be included in 
the metabolic models constructed to simulate in vitro growth.  
 
 
 
Figure 4.5.3. Functional distribution of essential genes predicted using 
TRADIS, but not present in the genome-scale metabolic model. The 
number of genes in each category is shown. There are 294 genes in total.  
 
A single gene deletion analysis was performed on to the genome-scale 
model of B. pseudomallei K96243 SEED272560_3. Deletion of a gene forces 
fluxes through associated reactions to be zero. A gene is marked as essential 
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when maximum growth rate (biomass production) is zero upon the gene’s 
deletion. Gene essentiality is analysed separately in different media 
compositions.  
13 different media were chosen from the MODEL SEED. Media 
compositions are listed in Table 2. There was no growth in media with Dulcitol, 
D-Alanine, D-Galactose, D-Saccharic Acid, and L-Arabinose as carbon sources. 
The growth rates in LB medium, D-Mannose, D-Trehalose, D-Glucose, L-
Aspartic-Acid, L-Proline, N-Acetyl-D-Glucosamine, and Succinic-Acid are 
presented in Table 4.5.1. 
 
Table 4.5.1. In silico growth rates in different media 
 
In silico growth rate (h-1) 
In silico growth in LB medium 79.6347 
In silico growth in Base medium* 1.3070 
In silico growth in D_Mannose 0.4747 
In silico growth in D_Trehalose 0.4747 
In silico growth in Glucose 0.4747 
In silico growth in L_Aspartic_Acid 0.3569 
In silico growth in L_Proline 0.3714 
In silico growth in 
N_Acetyl_D_Glucosamine 0.8713 
In silico growth in Succinic_Acid 0.3569 
In silico growth in Dulcitol no growth 
In silico growth in D_Alanine no growth 
In silico growth in D_Galactose no growth 
In silico growth in D_Saccharic_Acid no growth 
In silico growth in L_Arabinose no growth 
   * Based on the minimal media required for in silico growth in glucose 
c Based on media in SEED Model database 
   
The gene essentiality for in silico growth was compared to the predictions 
made using TRADIS. For each single gene deletion, the ability to grow is 
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assessed in the given media. The essentiality predictions for all the genes 
present in the model are presented in Table 4.5.2. Genes highlighted in blue 
are true positives, which were identified as essential both in LB medium 
simulations and in TRADIS. Genes highlighted in green are false positives 
(essential in LB medium simulations, not essential in TRADIS); in red are false 
negatives (not essential in LB medium simulations, essential in TRADIS); in 
yellow are true negatives (not essential in LB medium simulations and in 
TRADIS). The number of genes is presented in Table 4.52. We chose the LB 
medium simulations for comparison as the TRADIS experiments are performed 
in LB medium. The F score is calculated as 0.47. For established model 
organisms such as E. coli, about 90% of essential genes can be predicted using 
FBA [40]. Lower accuracy (60-80%) is achieved for other organisms [239,240]. 
Although B. pseudomallei FBA model presented here is not curated with any 
experimental data, essential genes are predicted with 79% accuracy. This 
attests to the power of the FBA model. The identification of essential genes and 
non-redundant metabolic pathways could aid to identify potential new drug 
targets.  
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Table 4.5.2 Comparison of the number of genes predicted to be essential / 
not essential in simulations of the genome-scale metabolic B. 
pseudomallei model versus experimental data obtained using TRADIS. 
  
Gene essentiality using TRADIS 
Essential Not essential 
Gene essentiality 
predictions 
 in silico growth in 
LB medium 
Essential 113 156 
Not essential 98 815 
 
4.6 Reduction of the genome-scale metabolic network 
The availability of fully sequenced annotated genomes has facilitated the 
construction of genome-scale models for different organisms. The complexity 
and capacity of these models are expanding with new biological knowledge. 
High amounts of computational power can be required to analyse genome-scale 
metabolic models. As the size of the models increase, it becomes more difficult 
to apply certain stoichiometric methods (i.e. enumeration of elementary modes). 
Furthermore, capturing basic metabolic principles are not easily achievable 
when one has to interpret huge numbers of patterns arising from thousands of 
reactions and metabolites. Often the fundamental features of an organism’s 
metabolic regulation are governed by core networks. Thus, it is useful to reduce 
the genome-scale models into smaller core models able to capture the capacity 
of the large models. This also simplifies experimental efforts of having to 
measure large sets of fluxes for validation purposes. Parameter dependent 
models, such as kinetic models, can only be reliably developed for small-scale 
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models. Network reduction allows focusing on the sub-modules of interest 
within the genome-scale network. 
The NetworkReducer algorithm [241] offers an automated procedure to 
reduce the genome-scale metabolic constructions to meaningful core models 
preserving the capabilities of the large network. The algorithm accepts a set of 
reactions and metabolites together with a subset of protected metabolites and 
reactions. Often the reactions and metabolites of central metabolism are 
selected. A typical phenotype is to preserve biomass production. First, the 
feasibility of the protected functions is checked and the blocked reactions are 
removed. In the following network-pruning step, the non-protected parts of the 
network are deleted one by one if they are dispensable for the protected 
phenotypes. This can be followed by a compression step, which lumps the 
remaining reactions together to further reduce the network size.  
The NetworkReducer algorithm was applied to the genome-scale model 
of Burkholderia pseudomallei K96243 SEED272560_3. By protecting biomass 
production on glucose uptake, the number of reactions was reduced from 1440 
to 498 (SEED272560_3_Pruned_1, Table 4.6.1). The trehalose cycle was not 
preserved in the resulting network, SEED272560_3_Pruned_1, implying that it 
is possible for the reduced networks to lose non-protected functionalities. 
Nonetheless, it would be desirable to develop a model comprising the trehalose 
cycle to study the general structural properties of the cycle or to evaluate the 
synthesis of certain products or to discover various optimal states. The network 
reduction process was repeated by protecting trehalose uptake and utilization 
reactions in addition to central metabolism (biomass production on glucose 
uptake is kept as the protected phenotype). The resulting reduced network 
(SEED272560_3_Pruned_2) contained 564 reactions and includes the 
 170 
trehalose pathways. Out of these 564 reactions, 499 are in common with the 
reactions of SEED272560_3_Pruned_1.  
 
Table 4.6.1 The genome-scale and reduced models of B. pseudomallei 
K96243 SEED272560_3 
 SEED272560_3 
SEED272560_3_Pru
ned_1 
SEED272560_3_Pru
ned_2 
Metabolites/Comp
ounds 1262 509 554 
Reactions 1440 498 564 
Growth rate 
(biomass 
production) 
1.3070 1.3070 1.3070 
 
4.7 Elementary flux mode analysis 
The metabolic capacity of the system can be explored using Elementary 
Flux Mode analysis (EFM) [242]. EFM calculates the feasible routes through a 
network identifying steady state pathways. This allows the network to be 
decomposed into fundamental functional units. Within these identified functional 
routes, inhibition of one enzyme leads to failure of the steady-state flux in the 
network. Thus, it is possible to systematically analyse the essentiality of genes 
for certain capabilities of the network. 
Enumeration of the full set of EFMs for large-scale models is highly 
computationally intensive as the algorithm iterates through a large number of 
combinatorial paths. While we were not able to enumerate the EFMs for the 
original SEED272560_3 model, network reduction provided smaller-scale 
networks for which we could run the EFM analysis. The number of EFMs was 
considerably smaller in SEED272560_3_Pruned_1 compared to 
SEED272560_3_Pruned_2. This could be due to the removal of redundant 
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paths in the NetworkReducer algorithm. Imposing the maintenance of the 
trehalose cycle reactions introduces a large number of combinatorial paths. 
While the number of EFMs for SEED272560_3_Pruned_1 is sufficient small to 
interpret them biologically, SEED272560_3_Pruned_2 allows us to explore the 
role of trehalase on the network capacity. When the trehalase gene was 
deleted, giving the model SEED272560_3_Pruned_2 (ΔtreA), the number of 
EFMs decreases (Table 4.6.2). This could suggest a loss in metabolic capacity. 
The biological interpretation of the absent modes is to be devised. These 
modes can point to different ways of trehalose being utilised and fed into 
different parts of metabolism. The modes that are lost in the trehalase mutant 
can be essential for the metabolic network to operate in steady state for cell 
growth and maintenance. This would provide insight into the loss of virulence in 
the trehalase mutant.  
 
Table 4.6.2. Elementary Flux modes of the genome-scale and reduced 
models of Burkholderia pseudomallei K96243 SEED272560_3 
 Number of Elementary Flux Modes 
SEED272560_3 Not enumerated 
SEED272560_3_Pruned_2 
SEED272560_3_Pruned_2 
(ΔtreA) 
1995515 
1311832 
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Prior work has documented the significance of trehalase mutation in infection 
with B. pseudomallei [98]. Modelling approaches have been applied to decipher 
the mechanisms through which trehalose metabolism regulates the adaptation 
of yeast to changing conditions. However, these studies have only focused on 
trehalose-phosphate synthase mutations. 
In this chapter, a detailed kinetic model of the trehalose cycle was 
studied to evaluate the effects on the metabolite concentrations of trehalase 
mutation. Transcriptomics data of B. pseudomallei was incorporated to simulate 
the dynamics of trehalose metabolism during infection. The interaction of 
trehalose cycle with glycolysis was studied for the trehalase mutation. Future 
studies should test the simulation results using laboratory experiments (i.e. 
evaluate the changes in metabolite concentrations using mass spectrometry). 
The trehalose metabolism in bacteria is not limited to the trehalose cycle 
(TPS/TPP pathway-trehalase). Future work should include additional 
interactions that B. pseudomallei trehalose may possess (such as trehalose 
synthase, Figure 4.7.1.). 
 
 
Figure 4.7.1. Network of proteins interacting with B. pseudomallei trehalase.  
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CHAPTER 5. CONCLUSIONS AND FUTURE WORK 
5.1 Summary 
It is crucial to provide completely new approaches to understanding the 
neglected B. pseudomallei, as this thesis has done, for the following reasons:   
- B. pseudomallei is widely distributed in many regions worldwide and the 
number of melioidosis cases are much higher than expected [112]. 
- B. pseudomallei lives in the environment, soil and water.  There are 
multiple infection routes; inhalation, ingestion, or skin inoculation.  
- Melioidosis is greatly under-recognised, difficult to diagnose due to lack 
of disease-specific symptoms. 
- B. pseudomallei is intrinsically antibiotic resistant and melioidosis has a 
high mortality rate.  
Previous work has highlighted the dangers of overlooking this infection 
and calls for immediate control measures, but the understanding of B. 
pseudomallei interference and melioidosis is far from complete. Contributing to 
this understanding, this thesis explored a systems approach to expand the 
existing knowledge about the bacterium’s ability to survive and infect host cells.  
- A novel approach employed by this thesis was to investigate the role of 
host DNA methylation during B. pseudomallei infection. The findings 
presented in this thesis provided the first compelling evidence of 
epigenetic changes in the host occurring following B. pseudomallei 
infection.  
- Equally importantly, this thesis employed mathematical modelling to 
elucidate the metabolic regulation of B. pseudomallei. The predictions 
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demonstrated in this thesis emphasise mechanisms of which the 
trehalose pathway may contribute to infection.  
One particular strength of this thesis’s methodology and outcomes is that 
such approaches can be applied to other diseases and pathogens. Due to its 
interdisciplinary nature, this thesis was able to demonstrate the benefits of 
combining biological experiments with mathematical analyses to achieve a 
more complete picture of disease. This will stimulate a wider understanding of 
the applications of systems biology to host-pathogen research and defence 
needs.  
The main findings of this thesis are as follows. Chapter 2 established an 
in vitro infection model to quantify genome-wide patterns of DNA methylation in 
B. pseudomallei infected human macrophages. It offered the following 
discoveries: 
- Reproducible infection induced differentially methylated positions (DMPs) 
were identified.  
- DMPs were located in heavily, partially, and sparsely methylated regions.  
- Most of the methylation changes in infected macrophages were losses in 
methylation rather than gains.  
- There were five different differential methylation patterns: constant, early, 
late, transient, and oscillatory responses.  
- A range of genes associated with the immune response to infection were 
differentially methylated, e.g. immune responses including cytokines and 
chemokines. DMPs were located in the vicinity of genes involved in 
inflammatory responses, actin regulation, nitric-oxide generation, T-cell 
responses, ubiquitination. 
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- qPCR analysis and comparisons with publically available transcription 
data identified genes that are both differentially methylated and 
differentially expressed.  
- Comparison with the publically available DNA methylation changes 
during infection with other pathogens identified pathogen-specific and 
pathogen-common changes. 
In Chapter 3, whole blood DNA methylation levels of patients diagnosed 
with septicemic melioidosis and healthy subjects were measured. Four major 
discoveries emerged: 
- DNA methylation profiles of septicemic melioidosis patients were distinct 
from those of healthy individuals and individuals with type 2 diabetes 
mellitus.  
- Differentially methylated positions in melioidosis patients were generally 
hypo-methylated compared to healthy subjects.  
- There were also differences in DNA methylation on large genomic 
regions (DMRs). 
- DMPs and DMRs map to genes associated with hyper-inflammatory and 
immunosuppressive responses attesting to their potential use as 
biomarkers. 
Chapter 4 applied mathematical modelling approaches to investigate the 
role trehalose metabolism in virulence. These approaches can be summarised 
as: 
- Trehalose pathway of B. pseudomallei was constructed using literature 
survey and databases. The genes/enzymes involved in B. pseudomallei 
trehalose pathway had high sequence identity to E. coli and S. cerevisiae 
genes/enzymes.        
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- While in yeast, glycolysis is affected in trehalose pathway mutant via 
regulation of the first step of glycolysis, no evidence was found for this 
mechanism in B. pseudomallei. 
- Simulations of trehalase mutation in kinetic model of yeast and the model 
modified for B. pseudomallei showed similar responses (i.e. increase or 
decrease in the metabolite concentration, accumulation of trehalose). 
- B. pseudomallei transcriptional changes were incorporated into the 
kinetic model. 
- A single gene deletion analysis was performed on the genome-scale 
metabolic model of B. pseudomallei.  
- The genome-scale metabolic model of B. pseudomallei was reduced to a 
core model and elementary flux modes were calculated.  
 
The findings presented in Chapter 2 and Chapter 3 provide evidence for the 
role of DNA methylation in infection. The in vitro model established in Chapter 2 
enables measuring DNA methylation changes in a controlled environment. As 
DNA methylation is greatly affected by environmental factors, the use of an in 
vitro model is beneficial in detecting differences that are solely due to infection. 
Elaborate study designs (i.e multiple time points) can be developed using in 
vitro models. However, in vitro studies do not always reflect the physiology of 
the human body. In fact, DNA methylation signatures identified in Chapter 2 are 
mostly distinct from the signatures identified in Chapter 3. The in vivo study 
established in Chapter 3 is beneficial in identifying biomarker panels for 
infection directly in patients. Not only these markers are biologically more 
relevant, DNA methylation signatures observed in the human blood can be 
effectively harnessed to develop diagnostic tests as it is a fairly easy procedure 
 177 
to draw blood from patients. However, accurate results can only be obtained 
after validation in large cohorts. The combination of in vitro and in vivo studies is 
definitely beneficial in developing the most accurate biomarkers. Integration of 
in silico models can be central to study highly pathogenic bacteria such as B. 
pseudomallei. Chapter 4 demonstrated that mathematical modelling 
approaches could provide insight into bacterial metabolism. Exploiting these 
computational techniques is essential when wet laboratory experimentation is 
difficult due to the nature of the bacteria under study. Ultimately, integration of 
data from in vitro, in vivo and in silico models will lead to better understanding of 
complex disease.  
 
5.2 Limitations of the study 
As with all studies, the work presented in this thesis has a number of 
limitations to be considered.  Although Chapter 2 measures the DNA 
methylation during the time course of infection, this is only during the early 
stages of infection. Only 1 sample of RNA could be collected for each group in 
the replication experiment presented in Chapter 2. As this limits the power to 
detect significant associations with gene expression, no analysis was made in 
the general transcriptome response of U937 cells following infection by B. 
pseudomallei.  
Further, Infinium HumanMethylation450 BeadChip is the widely-used 
established technology for human methylomic analysis. Nonetheless, it should 
be taken into consideration that as it is a microarray-based technology it relies 
on predetermined probes to target methylation sites. Unlike bisulfite-sequencing 
technologies, Infinium HumanMethylation450 BeadChip (recently replace by 
Infinium MethylationEPIC Kit with greater coverage)  can not be used to target 
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new regions of interest. This limits the coverage of the human methylome 
achieved in this analysis and it should be noted that there could be infection-
induced differences in parts of the genome, which is not covered by the array. 
The study design employed in Chapter 2 does not answer whether 
differential methylation is a consequence of the direct interaction of bacterial 
methyltransferases with host cell DNA, or the consequence of modification of 
host cell methyltransferase activity.  
Further caveats are also required. While chapter 3 provides compelling 
evidence for the presence of DNA methylation differences in melioidosis 
patients, these differences should only be accepted as preliminary candidates 
for biomarkers as the number of samples assessed in this thesis is relatively 
low (i.e. discovery of clinically relevant biomarkers have been possible with 
sample sizes of hundreds [158,243,244]). 
A number of factors, such as medications and comorbidities, may affect 
analyses that used blood samples [139,243,245]. While the presence of 
comorbidities were taken into account in Chapter 3, the extent of effects each 
disease contributes to DNA methylation could not be distinguished. No 
information was available about the medications used by the patients. Smoking 
can be an important confounding factor in DNA methylation studies [246]; in this 
thesis the smoking status of the subjects were not known. Such factors could 
complicate data interpretation. 
There was no information on DNA methylation differences in sepsis 
caused by other pathogens. Therefore the analyses employed in this thesis 
could not distinguish whether the observed methylation differences were 
specific to septicemic melioidosis or common to sepsis caused by other 
infections.  
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Cell types also affect the conclusions drawn from the present research. 
This thesis compared genome-wide methylation differences between B. 
pseudomallei and M. tuberculosis [80] to identify pathogen-specific and 
pathogen-generic signatures. These studies used different cell types. As 
epigenetic processes exhibit cell type-specific patterns [247], this comparison 
has a limited power. Another factor complicating the direct comparison is that 
the studies used different technologies to measure DNA methylation and thus 
their coverage of the genome is different.  
The work discussed in Chapter 4 suffers from a lack of experimental data 
on the B. pseudomallei trehalose pathway. Enzyme kinetics of model organisms 
was used to model B. pseudomallei pathways. The metabolite concentrations 
were simulated, yet the predictions could not be tested against experimental 
levels. As such, the B. pseudomallei genome-scale reconstruction model used 
in Chapter 4 is a draft model rather than a complete curated model (not fitted to 
experimental data). This greatly affects the power of predictions made by the 
downstream gene essentiality and elementary flux mode analyses. 
 
5.3 Future work 
This thesis provides evidence for the role of DNA methylation in 
infectious diseases and provides a framework for future studies to assess the 
relation between metabolism and virulence.  
The presence of such DNA methylation differences associated with B. 
pseudomallei infection is an important new finding. Indeed, the work presented 
here offers exciting avenues for further research, and there are several ways 
that the findings of this thesis can be extended through new study..  
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Chapter 2 concentrated on understanding whether B. pseudomallei 
modulated DNA methylation in infected macrophages, rather than fully 
understanding the downstream consequences. A comprehensive temporal 
analysis of gene expression and proteome will enable to fully interpret the 
methylation data. In future, it is advisable that samples are taken at additional 
later time points to fully assess the time course of infection in macrophages. 
Further work will benefit from exploring whether the changes are pathogen-
initiated or pathogen-mediated. To this end, dead bacterial cells (i.e. heat killed 
as shown in Marr et al. [81]) can be used as an additional control in the infection 
model in order to understand whether just the passive presence of the 
molecular components of the pathogen are sufficient to initiate host response or 
whether the pathogen actively elicits the response. An alternative approach 
might assess the similarity between the host- and pathogen DNA 
methyltransferases. None of the bacterial effectors identified to date is known 
actively to modulate DNA methylation. However, only a limited number of 
effectors have been identified to date, and the repertoire is likely to be much 
greater than the current list. A study of the similarity of the enzymes of the host 
and the pathogen can be used to infer whether bacteria are capable of directly 
methylating host DNA. If so, blocking the bacterial enzymes’ function could be a 
further experiment to pursue.  
The associations presented in Chapter 3 need to be validated in larger 
cohorts. Further work is planned to recruit more melioidosis patients to achieve 
statistically powerful results. Care will be taken to collect information on subjects 
that can be a confounding factor such as received treatments, smoking status 
and underlying diseases. Longitudinally sampled cohorts will be recruited to 
assess the dynamics of DNA methylation changes during the course of 
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melioidosis. Subjects can be grouped in days post admission to hospital to 
assess the methylation changes during acute infection. Furthermore, samples 
from chronic melioidosis patients can be assessed to decipher whether the 
markers identified in acute patients are conserved. It would certainly be 
valuable to evaluate DNA methylation changes during sepsis caused by other 
pathogens. In fact, assessing patients with ordinary infections (i.e. common flu) 
may inform whether these methylation changes are specific to highly 
pathogenic species or are an ordinary host response to infection. 
Identifying methylation changes opens new opportunities to control 
infection. Currently, there are small molecules that manipulate epigenetic 
modifications: 5-Azacytidine and 5-aza-2’-deoxycitidine are the two most potent 
DNMT inhibitors that exhibit hypomethylating activity. However, these drugs act 
globally. Identifying and understanding specific methylation biomarkers will aid 
the development of specialized drugs in future.  
The concluding remarks of Chapter 4 emphasise the need for 
experimental data to validate the mathematical models. Mass spectrometry 
should be used to measure whether the metabolite levels shown in the model 
reflect the physiological behaviour of the system. Enzyme kinetic assays can 
help improve models by providing the kinetic constants specific for B. 
pseudomallei. The improved models, then, will have predictive power to test 
hypothesis, which are not feasibly tested experimentally.  
The trehalose metabolism in bacteria is not limited to the trehalose cycle 
(TPS/TPP pathway-trehalase). Future work should include any additional 
interactions B. pseudomallei trehalose may possess. Interestingly, a link 
between bacterial glycogen-, maltose-, and trehalose-metabolism has been 
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discovered [248]. It would be beneficial to model these interactions to provide a 
complete understanding of the dynamics of trehalose metabolism.  
Advancing the genome-scale metabolic models of B. pseudomallei will 
provide a framework to integrate information from a multitude of sources. 
Transciptomics, proteomics, metabolomics and epigenetics data of the host and 
pathogen can be incorporated into such models to achieve a holistic view of the 
host-pathogen interaction.  
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Mapping epigenetic changes to 
the host cell genome induced by 
Burkholderia pseudomallei reveals 
pathogen-specific and pathogen-
generic signatures of infection
Deniz Cizmeci1,*, Emma L. Dempster2,*, Olivia L. Champion3, Sariqa Wagley3, 
Ozgur E. Akman1, Joann L. Prior3, Orkun S. Soyer4, Jonathan Mill2,5 & Richard W. Titball3
The potential for epigenetic changes in host cells following microbial infection has been widely 
suggested, but few examples have been reported. We assessed genome-wide patterns of DNA 
methylation in human macrophage-like U937 cells following infection with Burkholderia pseudomallei, 
an intracellular bacterial pathogen and the causative agent of human melioidosis. Our analyses 
revealed significant changes in host cell DNA methylation, at multiple CpG sites in the host cell genome, 
following infection. Infection induced differentially methylated probes (iDMPs) showing the greatest 
changes in DNA methylation were found to be in the vicinity of genes involved in inflammatory 
responses, intracellular signalling, apoptosis and pathogen-induced signalling. A comparison of our 
data with reported methylome changes in cells infected with M. tuberculosis revealed commonality of 
differentially methylated genes, including genes involved in T cell responses (BCL11B, FOXO1, KIF13B, 
PAWR, SOX4, SYK), actin cytoskeleton organisation (ACTR3, CDC42BPA, DTNBP1, FERMT2, PRKCZ, 
RAC1), and cytokine production (FOXP1, IRF8, MR1). Overall our findings show that pathogenic-specific 
and pathogen-common changes in the methylome occur following infection.
Melioidosis is an infectious disease caused by the intracellular bacterial pathogen Burkholderia pseudomallei. 
A recent study has found that the incidence of this disease is likely to have been significantly underestimated1. 
B. pseudomallei adopts various strategies to survive and replicate within host cells2. Avoiding or resisting the 
antimicrobial activities in the phagosome of host cells2,3 allows escape into the cytosol, the induction of actin 
polymerization and cell to cell spreading4. The transcriptional response of humans or mice to B. pseudomallei 
infection reveals changes in the expression of multiple genes, including loci associated with the inflammatory and 
innate immune responses5–7. These changes might be driven actively by bacteria, or they may be the consequence 
of altered responses of host cells to the infection.
Recently, a role for epigenetic regulation of host cell function during bacterial infection has been suggested8,9. 
DNA methylation, occurring exclusively at cytosine residues in mammals, is one of the best understood epige-
netic mechanisms, playing a key role in transcriptional regulation during development and being increasingly 
implicated in a range of non-infectious diseases10. Epigenetic processes can be dynamic: they are influenced upon 
exposure to a range of external environmental factors and stochastic events in the cell11.
Few studies have investigated epigenetic changes in response to infection but there are reports of altered 
patterns on methylation in cultured cells infected with Helicobacter pylori12,13, Mycobacterium tuberculosis14 or 
Leishmania donovani15 and evidence that in mice the gut flora influences methylation of the IL-4 gene in intestinal 
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epithelial cells resulting in the down-regulation of TLR4 expression16. Some of these studies have focussed on 
selected genes12,16, others have profiled genome wide changes in the methylome13–15. These studies have revealed 
linkage between methylation events and the level of expression of associated gene(s).
In this study we determined genome-wide changes in DNA methylation in human macrophage-like U937 
cells following infection by B. pseudomallei. We identify widespread changes in host cell DNA methylation fol-
lowing infection, and show that these are enriched in the vicinity of loci involved in inflammatory responses, 
intracellular signalling, apoptosis and pathogen-induced signalling. By comparing our data with the previously 
reported data we have identified genes, which show differential patterns of methylation in cells infected with 
different pathogens.
Results
Infection Model. U937 cells can mature and differentiate to adopt the characteristics of mature human 
macrophages17. We established the pattern of infection of U937 cells, which had been activated with interferon 
gamma (IFN-γ ), by B. pseudomallei K96243 expressing red fluorescent protein (RFP). At 2 hours (T2) post infec-
tion, 74% of the human cells were infected (Supplementary Fig. 1) and the number of intracellular bacteria was 
106 CFU/ml (Fig. 1). After 4 (T4) or 6 hours (T6) post infection the number of intracellular bacteria had declined 
to 103 CFU/ml. No intracellular bacteria were recovered at 24 hours post infection (T24). We and others18 have 
found that the activation of macrophages with IFN-γ dramatically enhances the ability of the cells to control 
infection with B. pseudomallei and this explains the progressive reduction in the number of intracellular bacteria.
Multiple loci in U937 cells show reproducible changes in DNA methylation after B. pseudomallei 
infection. We infected U937 cells with B. pseudomallei and mapped changes in host cell DNA methylation 
at T2 and T4. DNA from the infected or uninfected (control) U937 cells was collected from two technical repli-
cates and two experimental replicates at each time. We subsequently performed a second experiment following 
the same protocol but with additional sampling times included to provide samples at 1 hour (T1), 2 hours (T2), 
3 hours (T3) and 4 hours (T4) post infection. The experimental design is shown in Supplementary Fig. 2.
DNA methylation was quantified using an Illumina 450K HumanMethylation array, with pre-processing, 
normalization and stringent quality control undertaken. In our first experiment we identified 
differentially-methylated positions (DMPs) between infected and uninfected cells at T2 or T4, allowing us to 
identify infection-induced DMPs (iDMPs).
Reasoning that larger differences are potentially more biologically meaningful, our primary focus was on 
iDMPs characterized by > 10% DNA methylation difference between groups19. We identified 10,279 iDMPs (54% 
hypo-methylated, 46% hyper-methylated) at T2 and 4850 iDMPs (57% hypo-methylated, 43% hyper-methylated) 
at T4, with 642 iDMPs differentially methylated at both T2 and T4 (Fig. 2). We next performed a second experi-
ment to identify consistent changes and obtained a stringently-filtered dataset of 388 conserved iDMPs conserved 
between the two experiments and which were used for subsequent analysis. These DNA methylation changes 
were highly correlated across both experiments (T2: r = 0.83, p < 0.0001, Supplementary Fig. 3a; T4: r = 0.73, 
p < 0.0001, Supplementary Fig. 3b). 264 iDMPs were identical at T2, 141 iDMPs were conserved at T4 and 17 
iDMPs conserved at both T2 and T4 (Supplementary Table 1).
The conserved iDMPs were not uniformly distributed across the genome (Supplementary Table 2). We found 
a highly-significant over- representation of infection-induced DNA methylation at probes located in the first 
exons of genes (compared to the frequency of positions in all probes on the Illumina 450K array analysed, relative 
enrichment (95% CI) = 3.34, P = 1.11 × 10−22).
In addition to quantifying DNA methylation at T2 and T4 in experiment 1 and 2, we profiled samples col-
lected at T1 and T3 in experiment 2 (Supplementary Fig. 2). Distinct patterns of DNA methylation across the four 
time points were observed (Table 1); 21 probes (5.41%) showed consistent changes in DNA methylation across all 
time points in both experiments (for example cg17676428 (Fig. 3a)), 23 (5.93%) showed large changes at the early 
time-points that diminished at the later time-points (for example cg15470658 (Fig. 3b)), 55 (14.18%) displayed a 
Figure 1. Bacterial loads at different time points in U937 cells infected with B. pseudomallei (MOI = 10). 
Bacterial load was measured as colony forming units (CFU).
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lag in response, with DNA methylation changes only occurring at the later time points after infection (for exam-
ple cg14113958 (Fig. 3c)), 99 (25.52%) showed a transient (for example cg14173033 (Fig. 3d)), and 190 (48.97%) 
an oscillatory response. The losses of methylation were more prominent compared to gains in DNA methylation 
patterns, especially in iDMPs exhibiting a constant response.
To explore the biological significance of the genes mapping to the set of iDMPs, we annotated their corre-
sponding gene ontology (GO) term and searched for over-representation of categories using the package GOseq, 
which weights genes based on number of probes per gene. Enriched biological functions were summarised and 
visualised in Fig. 4 using semantic similarity, which provides a measure of functional similarity. Functionally 
similar GO terms appear closer in the plot.
Comparison with publically available transcription data. We compared the iDMPs with transcrip-
tomic data from a previous study of B. pseudomallei infection in humans which identified 2604 human genes, that 
were differentially expressed in patients with septicemic melioidosis6. Of these, 76 genes were annotated to the 
iDMPs we identified in our study. These included genes involved in immune system process (BCL11B, CDKN1C, 
GLMN, HLX, IL1R2, IRF8, MAEA, MEF2C, MR1, NBEAL2, PRKCH, PTGDR2, STK3, TNFSF8, TRIM27), 
response to stress (ADRB2, APBB1IP, DTNBP1, FBXO31, MARCH1, MSRA, PKD2, SCARB1, ZMYND11), and 
inflammatory response (CD44, HDAC4, HIF1A, IL18RAP, TOLLIP, IER3, NT5E).
Figure 2. Quantification of Infection-induced iDMPs. * iDMPs conserved between the two experiments.
Category Number of probes Hyper-methylated Hypo-methylated
A: constant response 21 3 18
B: early response 23 10 13
C: late response 55 11 44
D: transient response 99 42 57
E: oscillatory 
response 190 NA NA
Table 1.  Number of iDMPs assigned to categories based on differential methylation patterns. Signatures 
with differential methylation at all time points (1 hour (T1), 2 hours (T2), 3 hours (T3) and 4 hours (T4) post 
infection) were classified as, constant hyper- or constant hypo-methylated probes. Signatures with differential 
methylation at early time points (T1, T2, T3) and no change at the T4 time point were classified as early 
response probes. Signatures with no response at the T1 time point and with differential methylation at later 
time points were classified as late response probes. Signatures with no response at T1 and T4 and differential 
methylation at T2 or T3 were classified as transient responses. The remainder of the patterns were classified as 
oscillatory probes. NA = not applicable.
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Comparison with publically available DNA methylation changes during infection with other 
pathogens. Innate immune cells, such as macrophages or dendritic cells, are recruited in response to path-
ogens to initiate defense mechanisms. While this study explores DNA methylation changes in macrophages, 
a recent study identified epigenetic regulation in human dendritic cells before and after in vitro infection (at 
Figure 3. Differential methylation patterns. Each panel shows a representative gene, showing a particular 
temporal pattern as discussed in the main text and methods. The error bars represent the standard deviation of 
the methylation levels of the first experiment samples: (a) constant hypo-methylation; (b) early response hypo-
methylation; (c) late response hypo-methylation; (d) transient response hypo-methylation.
Figure 4. Gene ontology terms enriched (p < 0.05) in genes mapping to conserved iDMPs. The colour scale 
represents the p-values calculated using GOseq. The non-redundant gene ontology terms are clustered using 
REVIGO.
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18 hours after infection) with Mycobacterium tuberculosis14. The proportions of iDMPs compared to the total num-
ber of sites probed were comparable to our study (0.000912 in our study; 0.000649 in the M. tuberculosis study). 
We did not identify any stringently-filtered iDMPs which were identical in cells infected with B. pseudomallei 
or with M. tuberculosis (Supplementary Fig. 4). However, when we considered the genes to which these iDMPs 
mapped we identified 121 genes (median distance of ~95 kb from the nearest transcription start site), which 
showed differential methylation in both studies (Supplementary Table 3). These included genes involved in T cell 
responses (BCL11B, FOXO1, KIF13B, PAWR, SOX4, SYK), actin cytoskeleton organization (ACTR3, CDC42BPA, 
DTNBP1, FERMT2, PRKCZ, RAC1), and cytokine production (FOXP1, IRF8, MR1) (Fig. 5).
Discussion
This study expands the limited knowledge on the role of epigenetics during infection by reporting temporal 
changes to the genome-wide methylome of human cells infected with a bacterial pathogen. For our study we have 
used human macrophages activated with interferon gamma, because we believe that this more accurately reflects 
the state of macrophages during sepsis caused by B. pseudomallei. We found that a range of genes associated 
with the immune response is differentially methylated in the host after infection with B. pseudomallei and these 
changes were replicated in a second experiment. These methylation events were associated with genes encoding 
cytokines, chemokines and their receptors (CCR4, IL1R2, IL18RAP, TNFSF15, TNFSF8, CCL28) and signalling 
pathways (CASP8AP2, TOLLIP, SYK, ZBP1, MAP4K4, MBIP). Immune system processes were also enriched 
in genes near iDMPs identified in this study and genes differentially expressed in patients’ blood infected with 
B. pseudomallei. Increased expression of the TOLLIP gene has previously been reported in humans infected with 
B. pseudomallei6. The precise role of TOLLIP in protective immunity is still being clarified. One function of the 
protein is to interact with IL1RI, TLR2 and TLR4 after lipopolysaccharide (LPS) activation, thereby modulating 
the NF-κ B and JNK signaling pathways and consequently inflammatory responses to infection20. The role of 
B. pseudomallei LPS in virulence21 and the activation of TLR2 and TLR4 signalling during B. pseudomallei infec-
tion is well documented22–24. It is possible that the differential methylation of TOLLIP we have seen modulates the 
early immune response to B. pseudomallei LPS.
Another important feature of disease caused by B. pseudomallei is the ability of the pathogen to establish 
chronic or persistent infections. B. pseudomallei is an intracellular pathogen, and phagocytes are believed to 
be an important niche for growth and survival in the host25,26. The differential methylation of genes involved 
in memory T-cell responses, such as CD44, FOXO1 and FOXC1, might contribute to the inability of the host to 
mount responses capable of clearing infection. Other host defence systems involve interferon gamma and nitric 
oxide. Interferon gamma plays a key role in the control of B. pseudomallei infection27,28 and suppression of the 
host innate response to B. pseudomallei infection has previously been attributed to downregulation of the type I 
interferon gamma signalling pathway by the bacterial effector TssM29. Previously CD44high CD8 T-cells have been 
shown to be an important source of interferon gamma30 and we found evidence of differential methylation of 
CD44 in our study. We also found evidence of the differential methylation of a number of genes (IRF-8, IFNE and 
Figure 5. Gene ontology terms enriched (p < 0.05) in genes annotated to the iDMPs in B. pseudomallei 
and M. tuberculosis infections. The colour scale represents the p-values calculated using GOseq. The non-
redundant gene ontology terms are clustered using REVIGO.
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ZBP1), which are involved in the regulation of interferon gamma expression. Nitric oxide has potent antibacterial 
activity towards B. pseudomallei31,32. A DMP located upstream of the dimethylarginine dimethylaminohydrolase 
2 (DDAH2) gene that encodes an enzyme in the nitric oxide generation pathway is hypo-methylated at all time 
points. The differential methylation of the gene encoding the NOX4 NADPH oxidase that we have seen, might 
explain the activation of this enzyme in phagocytes infected by the bacterium33. Such observations provide new 
insights in the possible molecular mechanisms, which underpin suppression of the host response.
We also found differential methylation of genes associated with ubiquitination of proteins targeted for degra-
dation, including the SPSB4 and WSB1 gene products, which are associated with substrate recognition and the 
NEDD4L and SIAH1 genes encoding ubiquitin ligases. The deamidation of the NEDD8L protein by a B. pseu-
domallei type III effector protein (CHBP) has previously been demonstrated, and this triggers apoptosis of host 
cells34. However, the modulation of host cell ubiquitination has also been associated with the suppression of host 
immunity35 and the downregulation of the NF-kappaB/type I interferon signalling pathways has been attributed 
to the ubiquitination of signalling molecules29. Our findings provide additional insight into the mechanisms that 
contribute to modulation of the ubiquitination pathway.
The most significantly enriched GO terms in the set of iDMPs were cell adhesion related (FDR corrected 
P < 0.05). B. pseudomallei is known to promote the polymerisation of host actin at one pole of the bacterium in 
an ARP2/3- dependent manner36. This enables motility of the bacteria and is essential for the uptake of bacteria 
into cells and the spread of bacteria within and between cells. Several iDMPs map to genes involved in actin 
binding or polymerisation. These include CDC42BPA, a component of the BLOC-1 complex, which can inter-
act with WASH - a regulator of ARP2/337 and ACTR3, a major component of the ARP2/3 complex38. We also 
found differential methylation of one of the central regulators of actin polymerisation, the PAK1 p21-activated 
kinase39.
Our findings also suggest that there are some common targets for methylation in cells infected with patho-
gens. Most of the methylation changes in cells infected with M. tuberculosis or B. pseudomallei are losses rather 
than gains in methylation. A broadly similar trend has also been reported by Marr et al.15 who reported a larger 
proportion of hypo-methylated CpG sites in L. donovani infected macrophages. Overall it seems that there is a 
general trend toward demethylation of host cell DNA during infection. Our comparison of M. tuberculosis or B. 
pseudomallei induced changes in methylation patterns revealed that although a number of common genes were 
differentially methylated, there were no conserved iDMPs. However, since these studies used different cell types 
we cannot discount the possibility that there would be conserved iDMPs if the experimental conditions were 
identical.
We also found that the conserved iDMPs were significantly enriched in the first exon of genes, DNA meth-
ylation in this genomic compartment has been associated with transcriptional suppression40,41, suggesting 
that a large proportion of the infection associated DNA methylation changes observed could be altering gene 
transcription.
In summary, our work provides new insights into the extent to which infection with a bacterial pathogen 
results in differential methylation of host cell DNA. Our findings indicate that methylation of host DNA occurs 
on a much greater scale than previously suggested. None of the effector B. pseudomallei molecules identified to 
date have been shown to methylate host DNA. Whether differential methylation is a consequence of the direct 
interaction of bacterial methyltransferases with host cell DNA, or the consequence of modification of host cell 
methyltransferase activity awaits investigation.
Methods
Cell line and infection model. The human leukemic monocyte lymphoma cell line (U937, ATCC CRL-
1593.2) was maintained in RPMI 1640 supplemented with 10% foetal bovine serum (FBS) at 37 °C. U937 cells 
were differentiated to macrophage-like cells following exposure to 20 ng/ml (final concentration) of phorbol 
12-myristate 13-acetate (PMA) for 48 hours at 37 °C and differentiation evidenced by increased adherence 
to tissue culture flasks. A total of eight flasks (four for infected cells and four for uninfected controls) were 
prepared.
Overnight cultures of B. pseudomallei K96243 were diluted in L-15 medium and added to differentiated U937 
cells at a multiplicity of infection (MOI) of 10. Where indicated B. pseudomallei K96243 expressing red fluores-
cent protein (RFP) was used42. Uninfected controls in the remaining four flasks were overlaid with L15 medium 
only. The cells were then incubated at 37 °C for 2h to allow infection. The cells were washed 3 times with phos-
phate buffered saline (PBS) and incubated with fresh L15 medium containing 1 mg/ml kanamycin for 2 hr to kill 
extracellular bacteria. After 2 hrs the macrophage cells were held in fresh media containing 250 µ g/ml kanamycin 
to supress the growth of extracellular bacteria. At appropriate time points the cells were washed 3 times in warm 
PBS and lysed with 0.1% (vol/vol) Triton X-100. DNA was isolated using an AllPrep kit (Qiagen) and stored 
at − 80 °C until required. DNA yield was measured using a Nanodrop instrument with measurements between 
22.8–50.6 ng/ul.
Enumeration of adhesion and uptake of B. pseudomallei by U937 cells. At 1 hour (T1), 2 hours 
(T2), 4 hours (T4) and 24 hours (T24) post infection the cells were washed 3 times in warm PBS and lysed with 
0.1% (vol/vol) triton X-100. Serial dilutions of the cell lysate were plated onto LB agar to determine the intracel-
lular bacterial cell counts (Fig. 2).
Additionally at T2, cells were washed 3 times with PBS and overlaid with 200 µ l paraformaldehyde 0.4%, 
ensuring any coverslips were fully immersed. Cells were than incubated at room temperature for 30 minutes. PFA 
was removed and coverslips were washed twice with PBS for 1 hour for each wash. Coverslips were removed and 
stained with 4′ ,6-diamidino-2-phenylindole (DAPI) and cells visualized with epifluorescence. Eight fields of view 
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were visualised and the number of uninfected or infected U937 cells counted. The mean number of cells associ-
ated with bacteria at T2 was calculated (Fig. 1).
A second experiment was designed to enable verification of the results of the first experiment. Similar pro-
cedures were followed as described above and DNA collected from uninfected and infected cells at 1 hour (T1), 
2 hours (T2), 3 hours (T3) and 4 hours (T4) post infection.
DNA methylation analysis. The DNA methylation profile of the infected macrophage DNA was deter-
mined using the Infinium HumanMethylation450 BeadChip (450K) (Illumina Inc.) following the manufacturer’s 
instructions. The 450 k BeadChip interrogates DNA methylation at > 480,000CpG sites across the genome. Briefly, 
500 ng of genomic DNA was sodium bisulfite converted using the EZ-96 DNA Methylation kit (Zymo research, 
CA, USA) using the manufacturer’s instructions. Post-hybridisation allelic-specific single-base extension of 
the probes incorporates a fluorescent label enabling detection. Replicates were processed together on the same 
array to reduce batch effects. The data was extracted and the initial analysis was performed using GenomeStudio 
(2010.3) methylation module (1.8.5). For further details please see Pidsley et al.43.
Data Analysis. For each CpG site a beta value was generated by the relative intensity of the green fluorescent 
signal (methylated (M)) to the red and green signal combined (M/M+ U+ 100). Quality control checks and quan-
tile normalisation were implemented using WateRmelon43. Samples with more than 1% of sites with a detection 
p-value greater than 0.05 were removed as were probes with 1% of samples with a detection p-value greater than 
0.05. Probes were removed if they had a bead count less than 3 in 1% of samples. Cross-hybridizing probes were 
removed44, leaving 425496 probes for analysis. DMPs between infected and control cells were identified using 
∆ β cut-off of 0.1. iDMPs identified at T2 and T4 in the first experiment, were compared to the corresponding 
probes at the same time point in the second experiment. Probes exhibiting a ∆ β change in the same direction 
of = > 0.1 were taken for further analysis. Correlation of ∆ β values between the two experiments was meas-
ured using Pearson Correlation Coefficient. This set of replicated iDMPs were tested for enrichment of genomic 
regions using a two-tailed Fisher’s exact test, compared to the frequency of all probes on the Illumina 450 K array. 
iDMPs with consistent up or down-methylation throughout T1, T2, T3 and T4 were determined. The temporal 
methylation patterns were assigned to categories based on the change in score at successive time points. As many 
of the differential methylation patterns found in disease or environmental factors are characterized by smaller 
changes, in the range of 5%15, this criterion was selected to identify temporal patterns of differential methylation. 
Signatures with more than 5% differential methylation at all time points were classified as, constant hyper- (+ 5%) 
or constant hypo-methylated (− 5%) probes. Signatures with more than 5% differential methylation at early time 
points (T1, T2, T3) and no change at the T4 time point were classified as early response probes. Signatures with no 
response at the T1 time point and with more than 5% differential methylation at later time points were classified 
as late response probes. Signatures with no response at T1 and T4 and more than 5% differential methylation at 
T2 or T3 were classified as transient responses. The remainder of the patterns were classified as oscillatory probes.
Candidate genes were assigned to the probes using the GREAT software45, genes are allotted to genomic 
regions taking into account the functional significance of cis-regulatory regions. Gene ontology term enrich-
ment analysis was performed using the Bioconductor package GOseq46. Enriched gene ontology terms are 
selected based on the criteria of having p-value < 0.05. Redundant gene ontology terms were removed and the 
non-redundant gene ontology terms were clustered using semantic similarity measures (the simRel score) using 
REVIGO47.
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